Page last updated: 2024-11-08

povidone-iodine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Povidone-Iodine: An iodinated polyvinyl polymer used as topical antiseptic in surgery and for skin and mucous membrane infections, also as aerosol. The iodine may be radiolabeled for research purposes. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID410087
SCHEMBL ID1652685
MeSH IDM0017404

Synonyms (35)

Synonym
nsc-28655
nsc28655
nsc-26245
pvp-iodine
povadyne
disphex
isodine
molecular iodine; 1-vinylpyrrolidin-2-one
betadine
nsc26245
ultradine
povidone iodine
efo-dine
pvp iodine
bridine
pvp-i
isobetadyne
povidone-iodine
25655-41-8
1-ethenylpyrrolidin-2-one; molecular iodine
FT-0655804
1-ethenyl-2-pyrrolidinone; molecular iodine
A817952
AKOS015898248
SCHEMBL1652685
povidone.iodine
mfcd00084483
CPKVUHPKYQGHMW-UHFFFAOYSA-N
povidone (iodinated), european pharmacopoeia (ep) reference standard
A16118
1-vinylpyrrolidin-2-one compound with diiodine (1:1)
1-ethenylpyrrolidin-2-one;molecular iodine
Q241516
BCP28568
PD118263

Research Excerpts

Toxicity

35% povidone-iodine solution for three min are toxic to the articular cartilage of the knee in an experimental in vivo study in rabbits. Commonly used topical concentrations of PVI, vancomycin, and bacitracin are also toxic.

ExcerptReferenceRelevance
" These results suggest that with frequent-dosage regimens, preservation-free artificial tear solutions-1 and -2 are free of the toxic effects associated with preserved solutions."( Preservative-free artificial tear preparations. Assessment of corneal epithelial toxic effects.
Abelson, MB; Berdy, GJ; George, MA; Smith, LM, 1992
)
0.28
"The chemical, microbiologic, and toxic characteristics of povidone-iodine solution, a commonly used antiseptic agent, are addressed in a collective review of relevant works published from 1956 to the present."( Chemical and microbiologic characteristics and toxicity of povidone-iodine solutions.
Zamora, JL, 1986
)
0.76
" In contrast, bacitracin at the concentrations tested was safe for osteoblasts and tibiae."( Toxic effects of wound irrigation solutions on cultured tibiae and osteoblasts.
Kaysinger, KK; Kellam, JF; Nicholson, NC; Ramp, WK, 1995
)
0.29
"Ozonated solution may be safe and a useful antiseptic of the ocular surface prior to ophthalmic surgery."( Safety of ozonated solution as an antiseptic of the ocular surface prior to ophthalmic surgery.
Ishijima, K; Kashiwagi, K; Saito, K; Takahashi, H; Tsukahara, S; Wang, YD,
)
0.13
"Some of the views contrasting the beneficial and toxic effects of antimicrobials upon wound healing remain controversial."( The beneficial toxicity paradox of antimicrobials in leg ulcer healing impaired by a polymicrobial flora: a proof-of-concept study.
Braham, C; Fumal, I; Paquet, P; Piérard, GE; Piérard-Franchimont, C, 2002
)
0.31
" The povidone-iodine irrigation was discontinued because he had toxic plasma iodine levels."( Iodine toxicity treated with hemodialysis and continuous venovenous hemodiafiltration.
Albright, RC; De Chazal, I; Haugen, EN; Juncos, LA; Kanakiriya, S; Nath, KA, 2003
)
0.83
" In addition, a toxic difference was recognized between cells, in the order of Chang conjunctiva > SIRC > FRSK > human fibroblast for isodine and neojodine."( [Cytotoxic effect and influence of povidone-iodine on wounds in guinea pig].
Iwasawa, A; Nakamura, Y, 2003
)
0.6
" Experimental groups were compared by the logarithmic difference between the clinical and LD50 concentrations of a particular irrigant."( An in vitro evaluation of the cytotoxicity of various endodontic irrigants on human gingival fibroblasts.
Barnhart, BD; Chuang, A; Joyce, AP; Liewehr, F; Lucca, JJ; Roberts, S, 2005
)
0.33
" Shur-Clens, SAF-Clens, and saline were found to be the least toxic to fibroblasts (toxicity index 0); Dial Antibacterial Soap and Ivory Liqui-Gel were the most toxic (toxicity index 100,000)."( A toxicity index of skin and wound cleansers used on in vitro fibroblasts and keratinocytes.
Dimitrijevich, SD; Mills, JG; Prather, ID; Wilson, JR, 2005
)
0.33
"The objective of this study was to investigate the toxic effects of povidone-iodine (PVI)."( Toxic effects of povidone-iodine on synovial cell and articular cartilage.
Kaku, N; Kataoka, M; Torisu, T; Tsumura, H, 2006
)
0.91
"Iodopovidone can be used as an effective and safe agent for (chemical) pleurodesis (through tube thoracostomy), which is inexpensive and readily available."( Efficacy and safety of iodopovidone pleurodesis through tube thoracostomy.
Agarwal, R; Aggarwal, AN; Gupta, D, 2006
)
0.33
"Intracapsular debulking nephrectomy, leaving the ureter and capsule intact and with intracapsular instillation of betadine, was a safe technique to remove a delayed, failed allograft."( Debulking transplant nephrectomy leaving an intact ureter and instillation of betadine intracapsular is safe nephrectomy: fifteen years' experience.
Buhluli, A; Zomorrodi, A,
)
0.13
" Talc is slurry and povidone iodine is equally effective and safe pleurodesing agent for symptomatic malignant pleural effusion."( A study of comparison of efficacy and safety of talc and povidone iodine for pleurodesis of malignant pleural effusions.
Banerjee, SN; Chakraborty, M; Das, A; Das, SK; Halder, AK; Saha, SK, 2008
)
0.35
" However, little is known about their potential toxic properties."( [A comparative in vitro study of cell toxicity of clinically used antiseptics].
Goertz, O; Hirsch, T; Jacobsen, F; Niederbichler, A; Rittig, A; Seipp, HM; Steinau, HU; Steinstraesser, L, 2009
)
0.35
"Lavasept showed only slight to moderate toxic effects on cellular vitality and proliferation."( [A comparative in vitro study of cell toxicity of clinically used antiseptics].
Goertz, O; Hirsch, T; Jacobsen, F; Niederbichler, A; Rittig, A; Seipp, HM; Steinau, HU; Steinstraesser, L, 2009
)
0.35
" Furthermore, antimicrobial efficacy and toxic properties must be included in the clinical decision process for optimal therapy of chronic wounds."( [A comparative in vitro study of cell toxicity of clinically used antiseptics].
Goertz, O; Hirsch, T; Jacobsen, F; Niederbichler, A; Rittig, A; Seipp, HM; Steinau, HU; Steinstraesser, L, 2009
)
0.35
" Data on the requirement for additional pleural procedures, adverse events and survival were collected."( Efficacy and safety of iodopovidone pleurodesis in malignant pleural effusions.
de Oliveira, SF; Neto, JD; Terra, RM; Vianna, SP, 2010
)
0.36
" Adverse events occurred after 11 (18%) pleurodesis procedures."( Efficacy and safety of iodopovidone pleurodesis in malignant pleural effusions.
de Oliveira, SF; Neto, JD; Terra, RM; Vianna, SP, 2010
)
0.36
" The primary endpoint was healing rate at 6 months, while secondary endpoints were healing time, time to achieve negative cultures, duration of antibiotic therapy, number of reinterventions, and adverse events."( A randomized controlled trial to examine the efficacy and safety of a new super-oxidized solution for the management of wide postsurgical lesions of the diabetic foot.
Del Prato, S; Gemignani, G; Goretti, C; Leonildi, A; Mazzurco, S; Menichetti, F; Piaggesi, A; Rizzo, L; Tascini, C; Tedeschi, A, 2010
)
0.36
"At 24h, Povidone-Iodine solution showed a significant toxic effect in the infant group."( Ototoxicity of Povidone-Iodine applied to the middle ear cavity of guinea pigs.
Ichibangase, T; Miyagi, M; Morizono, T; Nakagawa, T; Yamano, T, 2011
)
1.16
" Data on adverse events including chest pain, respiratory distress, allergic reactions, hypotension and failure of PD (the requirement for additional pleural procedures and recurrence) were collected."( Efficacy and safety of iodopovidone pleurodesis through chest tube in spontaneous pneumothorax.
Alizadeh, H; Mahmodlou, R; Rahimi-Rad, MH,
)
0.13
" Iodopovidone has been shown to be safe and effective for chemical pleurodesis in several studies."( Efficacy & safety of iodopovidone pleurodesis: a systematic review & meta-analysis.
Agarwal, R; Aggarwal, AN; Gupta, D; Khan, A, 2012
)
0.38
"Iodopovidone may be considered a safe and effective agent for chemical pleurodesis in patients with pleural effusions and recurrent pneumothoraces."( Efficacy & safety of iodopovidone pleurodesis: a systematic review & meta-analysis.
Agarwal, R; Aggarwal, AN; Gupta, D; Khan, A, 2012
)
0.38
"Iodopovidone is considered to be an effective and safe sclerosing agent in this animal model."( Effectiveness and safety of iodopovidone in an experimental pleurodesis model.
Acencio, MM; Antonangelo, L; Damico, FM; Marchi, E; Pitta, FG; Puka, J; Teixeira, LR; Terra, RM; Vargas, FS, 2013
)
0.39
"Our main objective is to describe the occurrence of common and severe adverse events after pleurodesis with two different doses of iodopovidone in patients with MPE."( Safety Profile of the Use of Iodopovidone for Pleurodesis in Patients with Malignant Pleural Effusion.
Andrade Neto, JD; Pego-Fernandes, PM; Pereira, SV; Teixeira, RM; Terra, RM, 2015
)
0.42
" During follow-up, adverse events, inflammatory markers, quality of life, and imaging exams were systematically evaluated and registered."( Safety Profile of the Use of Iodopovidone for Pleurodesis in Patients with Malignant Pleural Effusion.
Andrade Neto, JD; Pego-Fernandes, PM; Pereira, SV; Teixeira, RM; Terra, RM, 2015
)
0.42
" Overall, 227 adverse events possibly related to pleurodesis were registered, including 47 serious adverse events (in 34 patients)."( Safety Profile of the Use of Iodopovidone for Pleurodesis in Patients with Malignant Pleural Effusion.
Andrade Neto, JD; Pego-Fernandes, PM; Pereira, SV; Teixeira, RM; Terra, RM, 2015
)
0.42
"25%) of PI was found toxic to the rabbits' corneal endothelium, with progressive regeneration and complete healing within 2 weeks."( Safety of Intracameral Injection of Minimal Bactericidal Concentration of Povidone Iodine on the Corneal Endothelium in a Rabbit Model.
Ebeid, WM; ElKitkat, RS; Habib, EK; Shoukry, Y, 2016
)
0.43
" In addition, chlorhexidine in particular can produce both otologic and ocular toxic effects when used on the face."( Topical Approaches to Improve Surgical Outcomes and Wound Healing: A Review of Efficacy and Safety.
Cohen, JL; Friedman, A; Totoraitis, K, 2017
)
0.46
"The new protocol for chlorhexidine application permits surgical hand preparation with chlorhexidine, as a safe alternative to alcohol solutions, because it meets the standards defined by EN 12791."( Surgical hand preparation with chlorhexidine soap or povidone iodine: new methods to increase immediate and residual effectiveness, and provide a safe alternative to alcohol solutions.
Herruzo, R; Vizcaino, MJ; Yela, R, 2018
)
0.48
"Purpose Cancer therapy-associated paronychia (CAP) is a frequent adverse event associated with cytotoxic and targeted therapies that may impact dosing of anticancer therapies and patient quality of life (QoL)."( A randomized phase 2 trial of the efficacy and safety of a novel topical povidone-iodine formulation for Cancer therapy-associated Paronychia.
Anadkat, M; Barone, S; Capriotti, KD; Choi, J; Goldfarb, S; Kaffenberger, B; Kukoyi, O; Lacouture, M; McLellan, B, 2019
)
0.75
" One adverse event was reported in the 5% PVP-I group on Day 1-2 that was classified as not related to treatment."( Safety and tolerability of a one-time, in-office administration of 5% povidone-iodine in the treatment of adenoviral conjunctivitis: The Reducing Adenoviral Patient Infected Days (RAPID) study.
Gordon, MO; Harthan, J; Hartwick, AT; Huecker, J; Johnson, S; Margolis, MS; Migneco, M; Morettin, C; Olson, CK; Shorter, E; Than, T; Whiteside, M, 2019
)
0.75
"These results suggest ophthalmic 5% PVP-I used as a one-time treatment is safe and well tolerated by patients with Ad-Cs."( Safety and tolerability of a one-time, in-office administration of 5% povidone-iodine in the treatment of adenoviral conjunctivitis: The Reducing Adenoviral Patient Infected Days (RAPID) study.
Gordon, MO; Harthan, J; Hartwick, AT; Huecker, J; Johnson, S; Margolis, MS; Migneco, M; Morettin, C; Olson, CK; Shorter, E; Than, T; Whiteside, M, 2019
)
0.75
"Nasodine was not toxic and did not have detrimental effects on the paracellular permeability or CBF."( In vitro safety evaluation of a povidone-iodine solution applied to human nasal epithelial cells.
Psaltis, AJ; Ramezanpour, M; Smith, JLP; Vreugde, S; Wormald, PJ, 2020
)
0.84
"Application of Nasodine to HNEC-ALI cultures in vitro for up to 30 minutes was not toxic and did not affect the paracellular permeability or CBF."( In vitro safety evaluation of a povidone-iodine solution applied to human nasal epithelial cells.
Psaltis, AJ; Ramezanpour, M; Smith, JLP; Vreugde, S; Wormald, PJ, 2020
)
0.84
" Adverse events with oral use have not been reported in conscious adults or children."( Povidone-Iodine Use in Sinonasal and Oral Cavities: A Review of Safety in the COVID-19 Era.
Brown, SM; Capriotti, J; Frank, S; Tessema, B, 2020
)
2
" To evaluate the adverse effect of povidone-iodine on hearing, the bone conduction level was compared between groups at baseline and one month after exposure."( The safety of povidone-iodine solution in tympanoplasty: a randomised, triple-blind, placebo-controlled study.
Asadi, M; Barati, B; Ghazizadeh, M; Norouzi, G, 2021
)
1.26
"Povidone iodine is an effective and safe solution for pleurodesis."( Effectiveness and safety of povidone iodine for prolonged lung air-leak after lung surgery.
Abid, W; Ben Ayed, A; Chaari, Z; Frikha, I; Hentati, A, 2022
)
0.72
" Commonly used topical concentrations of povidone-iodine, vancomycin, and bacitracin are toxic to human chondrocytes ex vivo."( Ex Vivo Toxicity of Commonly Used Topical Antiseptics and Antibiotics on Human Chondrocytes.
Canavan, HE; Decker, M; Elghazali, NA; Garbrecht, E; Hill, DA; Nguyen, PAH; Packard, B; Salas, C,
)
0.4
" Five percent and lower concentration PI irrigation was safe and could not cause thyroid, kidney and liver damage."( The Toxicity and Antibacterial Effects of Povidone-Iodine Irrigation in Fracture Surgery.
Huang, X; Lv, W; Wang, D; Zhou, J, 2022
)
0.99
"35% povidone-iodine solution for three min are toxic to the articular cartilage of the knee in an experimental in vivo study in rabbits."( Chondrotoxic effects of tranexamic acid and povidone-iodine on the articular cartilage of rabbits.
Buzelin, MA; de Abreu E Silva, GM; de Andrade, MAP; de Oliveira Campos, TV; Nunes, CB; Pimenta, FS, 2023
)
1.73

Pharmacokinetics

ExcerptReferenceRelevance
" The method was successfully applied to study the pharmacokinetic of PVP-I in rabbits after vaginal administration."( Optimization and validation of an ion-pair RP-HPLC-UV method for the determination of total free iodine in rabbit plasma: application to a pharmacokinetic study.
Cui, L; Fan, G; Wang, S; Wen, J; Zhou, T, 2009
)
0.35
" Half-life was determined using high-performance liquid chromatography."( Intraocular Pharmacokinetics of Povidone-Iodine and Its Effects on Experimental Staphylococcus epidermidis Endophthalmitis.
Byon, IS; Cao, J; Jung, JW; Kim, KH; Lee, JE; Yoo, JW; Yoon, IS, 2015
)
0.7
" The study design and the pharmacokinetic properties of PI solution ensured that dilute PI would not be effective in this study."( Povidone-iodine pharmacokinetics and study design.
Grzybowski, A; Koerner, J, 2020
)
2

Compound-Compound Interactions

The authors investigate the efficacy of povidone-iodine combined with antibiotic irrigation in reducing the CC rate.

ExcerptReferenceRelevance
"The effects of ultrasonic scaling in combination with povidone-iodine solution were examined clinically."( [A study of ultrasonic scaling in combination with povidone-iodine solution. (1)].
Kawasaki, H; Kawashima, E; Kobayashi, R; Nakagaki, N; Ogata, C; Ohno, S; Teranishi, Y; Ueda, M; Ushijima, S; Yamamoto, M, 1990
)
0.78
"The authors investigate the efficacy of povidone-iodine combined with antibiotic irrigation in reducing the CC rate."( Povidone-iodine combined with antibiotic topical irrigation to reduce capsular contracture in cosmetic breast augmentation: a comparative study.
Giordano, S; Lilius, P; Peltoniemi, H; Salmi, A, 2013
)
2.1
"To determine the clinical efficacy of recombinant human epidermal growth factor (rh-EGF) combined with povidone-iodine (PVI) on patients with pressure ulcers (PUs)."( Efficacy of Human-Recombinant Epidermal Growth Factor Combined with Povidone-Iodine for Pressure Ulcers and Its Influence on Inflammatory Cytokines.
Lv, D; Wang, X; Yong, L; Zhang, B; Zhang, R; Zhao, Z, 2022
)
1.17
" Of them, 50 patients who received conventional treatment were assigned to the control group (Con group), while 55 patients treated with rh-EGF combined with PVI were assigned to the observation group (Obs group)."( Efficacy of Human-Recombinant Epidermal Growth Factor Combined with Povidone-Iodine for Pressure Ulcers and Its Influence on Inflammatory Cytokines.
Lv, D; Wang, X; Yong, L; Zhang, B; Zhang, R; Zhao, Z, 2022
)
0.96
"All in all, rh-EGF combined with PVI has a definite curative effect on patients with PUs."( Efficacy of Human-Recombinant Epidermal Growth Factor Combined with Povidone-Iodine for Pressure Ulcers and Its Influence on Inflammatory Cytokines.
Lv, D; Wang, X; Yong, L; Zhang, B; Zhang, R; Zhao, Z, 2022
)
0.96

Bioavailability

ExcerptReferenceRelevance
" Hence the need for a controlled study to evaluate the bioavailability of the active component after penetration through burn eschar; the bactericidal efficacy of the cream and determination of the bactericidal time of the cream in comparison with 10 per cent PVP-I ointment."( Bactericidal efficacy of 5 per cent povidone iodine cream in Pseudomonas aeruginosa burn wound infection.
Cywes, S; De Wet, PM; Rode, H, 1990
)
0.28
" Water absorption rate constant was 29."( Critical evaluation of cadexomer-iodine ointment and povidone-iodine sugar ointment.
Fujii, K; Fujii, S; Noda, Y, 2009
)
0.6
" Water absorption rate constant of TR-PI with combination ratio of PI-sugar at 75% (TR-PI75, 18."( Physicochemical characterization of tretinoin tocoferil emulsion and povidone-iodine sugar ointment blend developed for improved regulation of wound moisture.
Fujii, S; Noda, Y; Saito, M; Sanagawa, A; Sobajima, Y; Watanabe, K, 2013
)
0.62
"The interaction of 3 water sanitizers (sodium hypochlorite, iodine-polyvinylpyrrolidone, and citrate) utilized in poultry production on antibacterial activity and bioavailability of amoxicillin trihydrate (AMX) were studied."( Antibacterial activity of amoxicillin in vitro and its oral bioavailability in broiler chickens under the influence of 3 water sanitizers.
Gracia-Mora, J; Gutiérrez, L; Ledesma, C; Rosario, C; Sumano, H; Tapia, G, 2018
)
0.48

Dosage Studied

Since 2013, povidone-iodine pleurodesis was attempted in all patients with persistent chylothorax who failed conservative treatment. The concentration and dosing of povidoiodine (PI) solution used in surgical site prophylaxis are variable.

ExcerptRelevanceReference
" In order to determine if PVP-I is safe for treating corneal ulcers and conjunctivitis, we evaluated the ocular toxicity of frequent dosing in a rabbit model."( Polyvinylpyrrolidone iodine: corneal toxicology and epithelial healing in a rabbit model.
Burstein, NL; Gaster, RN; Miller, S; York, KK, 1988
)
0.27
" Occurrence of postoperative infections did not decrease as a result of the local treatment and dosage as described."( [Local metronidazole and PVP-iodine prevention before abdominal and vaginal hysterectomy].
Degenhardt, F; Kaulhausen, H; Lellé, RJ; Potel, J, 1986
)
0.27
"Different povidone/iodine (PI) dosage forms (e."( Evaluation of the effect of formulation type of povidone/iodine preparations on infection and wound healing.
el-Khalek el-Timawy, A; el-Sayed, AM, 1993
)
0.29
"Although the appropriate antibiotic agent and dosage are not yet established, the administration of intracameral antibiotics and the application of povidone-iodine on the conjunctiva significantly reduced the relative risk of postoperative endophthalmitis in this survey."( Endophthalmitis in cataract surgery: results of a German survey.
Dick, HB; Krummenauer, F; Pfeiffer, N; Schmitz, S, 1999
)
0.5
" Curative treatment is acyclovir at high dosage - 60 mg/kg/d - during 14 days for localized forms and 21 days for neurological and disseminated diseases."( [Modalities of treatment local and general, medicamentous or not, controlling neonate suspected to be infected/contaminated by HSV1 or HSV2].
Aujard, Y, 2002
)
0.31
" metalloproteinase release from the cells was differently affected depending on the dosage and class of antiseptic applied."( Mechanisms of delayed wound healing by commonly used antiseptics.
Bar-Or, D; Bar-Or, R; Craun, ML; Mains, CW; Rael, LT; Shimonkevitz, R; Slone, DS; Thomas, GW, 2009
)
0.35
"The study of the dose-response relationship of disinfectants is of great importance in treating infection, the objective being to use concentrations above the minimal bactericidal concentration (MBC)."( Study of the hormetic effect of disinfectants chlorhexidine, povidone iodine and benzalkonium chloride.
Espigares, E; Espigares, M; Fernández-Crehuet, M; Morales-Fernández, L; Moreno, E, 2014
)
0.4
" A main reason might be the concentration of the dosage form and its contact time with the periodontal tissues."( Povidone-iodine gel and solution as adjunct to ultrasonic debridement in nonsurgical periodontitis treatment: an RCT pilot study.
Attin, T; Imfeld, T; Ronay, V; Sahrmann, P; Schmidlin, PR, 2014
)
1.85
"Since 2013, povidone-iodine pleurodesis was attempted in all patients with persistent chylothorax who failed conservative treatment (no response to at least 10 days of total parenteral nutrition and maximum dosage of intravenous octreotide)."( Pleurodesis with povidone-iodine for refractory chylothorax in newborns: Personal experience and literature review.
Bagolan, P; Conforti, A; Fusaro, F; Morini, F; Scottoni, F, 2015
)
1.14
" Nevertheless, randomized studies on large neonatal population are required to precise: the risks and benefits of this procedure, thetiming and the modalities of its realization (duration of intervention, dilution and dosage of PVI) according to the patient`s field (gestational age,weight and associated morbidity)."( Povidone Iodine Pleurodesis for Refractory Congenital Chylothorax: A Review of Literature.
Ben Salem, H; Blibech, S; Bouziri, A; Douagi, M; Kasdallah, N; Kbaier, H, 2016
)
0.43
" An alternative dosing strategy uses dilute PI repetitively throughout cataract surgery (0."( Povidone-iodine concentration and dosing in cataract surgery.
George, MJ; Habib, MM; Koerner, JC; Meyer, DR; Rosco, MG,
)
1.57
" Furthermore there is no consistency between dosing and severity of withdrawal."( A Novel Approach to Avoid Baclofen Withdrawal When Faced With Infected Baclofen Pumps.
Collison, C; Hwang, RS; Pilitsis, JG; Prusik, J; Sukul, V, 2019
)
0.51
" Preoperative antibiotics were dosed within 1 hour in 90% of the postpathway cohort."( Implementing a Multidisciplinary Clinical Pathway Can Reduce the Deep Surgical Site Infection Rate After Posterior Spinal Fusion in High-Risk Patients.
Berry, J; Brustowitz, R; Cohen, L; Emans, J; Glotzbecker, M; Goobie, S; Gryzwna, A; Hedequist, D; Hresko, MT; McCann, ME; Miller, P; Snyder, B; Troy, M, 2019
)
0.51
"The concentration and dosing of povidone-iodine (PI) solution used in surgical site prophylaxis are variable."( Povidone-iodine concentration and in vitro killing time of bacterial corneal ulcer isolates.
George, MJ; Kissam, EA; Koerner, JC; Rosco, MG, 2018
)
2.21
"Purpose Cancer therapy-associated paronychia (CAP) is a frequent adverse event associated with cytotoxic and targeted therapies that may impact dosing of anticancer therapies and patient quality of life (QoL)."( A randomized phase 2 trial of the efficacy and safety of a novel topical povidone-iodine formulation for Cancer therapy-associated Paronychia.
Anadkat, M; Barone, S; Capriotti, KD; Choi, J; Goldfarb, S; Kaffenberger, B; Kukoyi, O; Lacouture, M; McLellan, B, 2019
)
0.75
" Future research should investigate the optimal concentration, dosing regimen and role of each agent in combination treatment and aim to use laboratory techniques to improve diagnosis and provide quantifiable outcomes."( Povidone iodine for the treatment of adenoviral conjunctivitis.
Dang, RM; Hui, A; Watt, K, 2021
)
0.62
"Povidone iodine was associated with the vaginal microbiome alterations after parturition, and its significant change was associated to the dosage of povidone iodine administered."( Association between vaginal microbiome alteration and povidone iodine use during delivery.
Geng, L; Huang, H; Li, H; Nie, C; Zhang, H; Zhu, Y, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,037)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990750 (24.70)18.7374
1990's464 (15.28)18.2507
2000's593 (19.53)29.6817
2010's780 (25.68)24.3611
2020's450 (14.82)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 67.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index67.07 (24.57)
Research Supply Index8.29 (2.92)
Research Growth Index4.69 (4.65)
Search Engine Demand Index212.23 (26.88)
Search Engine Supply Index3.52 (0.95)

This Compound (67.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials664 (20.04%)5.53%
Reviews251 (7.58%)6.00%
Case Studies290 (8.75%)4.05%
Observational16 (0.48%)0.25%
Other2,092 (63.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (171)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of Polyvinylpyrrolidone Iodine Concentrations on Postoperative Trismus and Swelling Using as an Irrigation Solution During Impacted Third Molar Surgery : a Randomized Clinical Study [NCT03894722]Phase 480 participants (Actual)Interventional2016-10-03Completed
Efficacy of Over the Counter (OTC) Povidone-Ioldine 5% for Treatment of Acute or Chronic Blepharitis [NCT01560962]100 participants (Actual)Interventional2012-01-31Terminated(stopped due to research staffs unable to continue.)
Pilot Evaluation of the Effect of Application Procedure on the Antimicrobial Effects of an Aqueous CHG and a Traditional Iodophor Scrub Paint [NCT00692484]Phase 3122 participants (Actual)Interventional2007-10-31Completed
A Randomized Controlled Trial to Investigate the Infectious Outcomes of Intrarectal Povidone-iodine Cleansing Plus Formalin Disinfection of Needle Tip During Transrectal Ultrasound Guided Prostate Biopsy [NCT03879486]1,257 participants (Actual)Interventional2017-05-31Completed
A Comparison of Chlorhexadine Gluconate Versus Povidone Iodine Surgical Preparation in Skin Bacterial Colony Counts for Elective Knee Replacement Surgery [NCT01184196]Phase 455 participants (Actual)Interventional2009-11-30Terminated(stopped due to ChloroPrep Wipes no longer available)
Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers [NCT04347954]Phase 1/Phase 247 participants (Actual)Interventional2020-08-15Completed
Reduction of Sars-CoV-2 Oral Viral Load With Prophylactic Mouth Rinse [NCT04719208]60 participants (Anticipated)Interventional2020-10-06Active, not recruiting
Chlorohexidine Versus Povidone Iodine as Apreoperative Ophthalmic Disinfectant [NCT03957291]Early Phase 1100 participants (Anticipated)Interventional2019-08-31Not yet recruiting
Efficacy of Diluted Betadine vs Antibiotic Installation Before Surgical Wound Closure in Prevention of Post Cardiac Surgery Wound Infection [NCT05276687]Phase 480 participants (Anticipated)Interventional2022-09-30Not yet recruiting
Comparison of the Effect of Applying Povidone-iodine and Chlorhexidine Solutions for Perinea Washing on Bacteriuria Rate and Type in Patients With Urinary Catheter in Intensive Care Unit [NCT02032394]Phase 4105 participants (Anticipated)Interventional2013-07-31Recruiting
Reducing Perioperative S. Aureus Transmission Via Use of an Evidence-Based, Multimodal Program Driven by an Innovative Software Platform (OR Path Trac) [NCT03638947]236 participants (Actual)Interventional2018-09-20Terminated(stopped due to Intermediate analysis produced strong enough results that full study not needed.)
Comparative Study of 2% Chlorhexidine Gluconate in 70% Isopropyl Alcohol Against 10% Sodium Hypochlorite as Skin Antiseptics in Human Volunteers [NCT01321125]Phase 330 participants (Actual)Interventional2011-04-30Completed
Skin Antisepsis With Chlorhexidine-Alcohol Versus Povidone Iodine-Alcohol, Combined or Not With Use of a Bundle of New Devices, for Prevention of Intravascular-catheter Colonization and Catheter Failure: An Open Label, Single Center, Randomized Controlled [NCT03757143]Phase 41,000 participants (Actual)Interventional2019-01-07Completed
Testing the Counter-irritating Efficacy of Topical Povidone-iodine in Thermal Burns; Comparison to Conventional Treatments [NCT01350713]280 participants (Anticipated)Interventional2011-07-31Not yet recruiting
Reducing Urinary Tract Infection Rates Using a Controlled Aseptic Protocol for Catheter Insertion [NCT03101371]Phase 299 participants (Actual)Interventional2017-10-10Completed
Pragmatic Multicentre FActorial Randomised Controlled triaL Testing Measures to reduCe Surgical Site Infection in lOw and Middle Income couNtries [NCT03700749]Phase 35,480 participants (Anticipated)Interventional2018-11-29Recruiting
Efficacy of a Dilute Betadine Lavage in the Prevention of Postoperative Infection in Revision Total Knee Arthroplasty [NCT01175044]Phase 4505 participants (Actual)Interventional2010-08-31Completed
Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine [NCT01179412]Phase 4172 participants (Actual)Interventional2004-07-31Completed
A Phase 3, Multicenter, Randomized, Evaluation Committee-Blinded Study to Assess the Efficacy of Topical Omiganan 1% Gel in Preventing Local Catheter Site Infections/Colonization in Patients Undergoing Central Venous Catheterization [NCT00231153]Phase 31,859 participants (Actual)Interventional2005-08-31Completed
Comparison of Honey and Povidone-iodine in Wound Healing on Acute Laceration Wounds: A Randomized Controlled Trial Study [NCT03641053]Phase 335 participants (Actual)Interventional2018-01-29Completed
Evaluation of Multiple Subgingival Irrigations With 10% Povidone Iodine After Scaling and Root Planing : a Randomized Clinical Trial [NCT03432975]20 participants (Anticipated)Interventional2017-12-18Recruiting
Addition of Pre-wound Closure Povidone Iodine Wash Versus Direct Wound Closure Effect on Surgical Site Infections: A Randomized Controlled Trial [NCT05077592]Phase 4760 participants (Anticipated)Interventional2021-09-18Recruiting
The Effect of Oral Antiseptic Gargles on the Oral Cavity Microbiome [NCT03141554]Phase 412 participants (Actual)Interventional2017-05-05Completed
Mashhad University of Medical Sciences [NCT02263196]Phase 1/Phase 296 participants (Anticipated)Interventional2014-09-30Recruiting
Subcutaneous Tissue Irrigation With Povidone Iodine in Decreasing the Rate of Surgical Site Infection Following Cesarean Section (Randomized Control Trial) [NCT03549702]1 participants (Actual)Interventional2017-01-01Completed
A Randomized Open-label Prophylaxis Trial Among Migrant Workers at High-risk of COVID-19 (DORM Trial) [NCT04446104]Phase 34,257 participants (Actual)Interventional2020-05-13Completed
CLinical Evaluation of Adults UNdergoing Elective Surgery Utilizing Intraoperative Incisional Wound Irrigation: A Randomized Controlled Trial (CLEAN Wound) [NCT04548661]2,500 participants (Anticipated)Interventional2023-08-02Recruiting
A Single Site Prospective Randomized Controlled Trial Comparing Chlorhexidine Gluconate and Povidone-Iodine as Vaginal Preparation Antiseptics for Cesarean Section to Determine Effect on Bacterial Load [NCT03133312]Phase 4100 participants (Actual)Interventional2017-05-02Completed
A Multicenter, Single Blind, Randomized Controlled Trial of Virucidal Effect of Polyvinyl Pyrrol-Iodine on SARS-CoV-2 as Well as Safety of Its Application on Nasopharynx & Oropharynx of COVID-19 Positive Patients [NCT04872686]Phase 3798 participants (Actual)Interventional2021-04-10Completed
"Comparison of Povidone Iodine and Hypochlorous Acid Used as a Preoperative Antiseptic in Neonatal Circumcision" [NCT05175027]60 participants (Actual)Interventional2021-05-05Completed
An Open Label, Multicenter, Randomized Trial of 2% Chlorhexidine-70% Isopropanol vs 5% Povidone Iodine-69% Ethanol for Skin Antisepsis in Reducing Surgical-site Infection After Cardiac Surgery [NCT03560193]Phase 43,316 participants (Actual)Interventional2018-09-10Completed
Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo: an Open Label Randomized Clinical Trial [NCT04549376]Phase 2200 participants (Actual)Interventional2020-07-01Completed
Impact of Ultrasound Guided Central Venous Catheterization on Complications in Obese Patients in Intensive Care Unit [NCT01154465]264 participants (Actual)Interventional2011-05-26Active, not recruiting
Effect of Washing With Clove Extract on Inflammation and Infection Place Logging Shaldon Needle [NCT02865980]60 participants (Anticipated)Interventional2016-08-31Recruiting
Evaluation of Posterior Segment Intrusion Using Miniplates in Skeletal ClassII Hyperdivergent Adolescence: A Randomized Control Trial [NCT02674191]24 participants (Actual)Interventional2016-05-31Active, not recruiting
Can Topical Vancomycin Prevent Periprosthetic Joint Infection in Primary Hip and Knee Arthroplasty? Multicenter Randomized Controlled Trial [NCT05972603]1,000 participants (Anticipated)Interventional2022-07-01Recruiting
A Phase 2, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Study to Evaluate Topical 2% Povidone-Iodine Gel (VBP-245) in Subjects With Verruca Vulgaris [NCT04253912]Phase 290 participants (Actual)Interventional2020-02-12Active, not recruiting
An Open-label Study to Assess the Antimicrobial Efficacy of ALT005 Ophthalmic Prep Solution (ALT005) Compared to Control (Sterile Saline) Following Dermal Administration in Healthy Volunteers [NCT01531699]Phase 354 participants (Actual)Interventional2012-02-29Completed
A Phase III Clinical Study Evaluating the Efficacy Of FST-201 Otic Suspension (Foresight Biotherapeutics, Inc.) Vs. Ciprodex Otic Suspension (Alcon Laboratories, Inc.) in Subjects With Acute Otitis Externa [NCT00961675]Phase 370 participants (Actual)Interventional2009-08-31Completed
A Randomized Controlled Study to Compare Chlorhexidine-Alcohol Versus Povidone-iodine for Surgical Site Preparation in Subjects Undergoing Medical Thoracoscopy for the Prevention of Infectious Complications [NCT05430308]100 participants (Anticipated)Interventional2022-04-18Active, not recruiting
A Randomized, Blinded, Single Center Study to Assess the Incidence of Surgical Site Infections in Breast Cancer Surgery After Preoperative Skin Preparation With Chlorhexidine 2% in Alcohol 70% (CHLORAPREP ®) Versus 10% Povidone-iodine [NCT02479347]Phase 42,158 participants (Actual)Interventional2013-03-31Completed
IrRigation of the INfected Pleural Space With antiSEptic Solution (RINSE) - a Proof of Concept Study [NCT05546762]Phase 244 participants (Anticipated)Interventional2022-09-19Recruiting
Evaluation of the Decolonization Rate and Acceptance of a Complete Nasal Decolonization Kit With Povidone Iodine for MRSA Patients [NCT05696132]Phase 250 participants (Anticipated)Interventional2023-02-28Not yet recruiting
Topical Ophthalmic Antiseptics and Reduction of Ocular Surface Bacterial Load Before Cataract Surgery: a Randomized Clinical Trial [NCT05974124]70 participants (Actual)Interventional2022-11-09Completed
Chlorhexidine vs. Betadine in Preventing Colonization of Continuous Femoral Catheters After Total Joint Arthroplasty [NCT00896402]0 participants (Actual)Interventional2014-07-31Withdrawn(stopped due to Funding inadequate)
Povidone Iodine Efficacy Study [NCT05272254]Phase 2246 participants (Anticipated)Interventional2022-09-15Recruiting
Prospective Randomized Evaluation of Emerging Novel Treatments for Infection Prophylaxis in Total Joint Replacement (PREVENT-iT) [NCT06126614]Phase 321,006 participants (Anticipated)Interventional2023-11-30Not yet recruiting
SURGX Antimicrobial Gel Versus Povidone-iodine Skin Incision Prep for the Prevention of Bacterial Seeding in Total Shoulder Arthroplasty [NCT05919888]Phase 460 participants (Actual)Interventional2023-06-26Completed
Prospective Randomized Evaluation of Emerging Novel Treatments for Infection Prophylaxis in Total Joint Replacement: A Pilot Study [NCT05084378]Phase 3500 participants (Anticipated)Interventional2022-03-11Active, not recruiting
The Efficacy of Topical Povidone - Iodine Rinses in the Management of Biofilm-associated Chronic Rhinosinusitis [NCT04097613]Early Phase 129 participants (Actual)Interventional2017-07-28Completed
A Comparison Between Povidone-iodine and Normal Saline in Vaginal Cleansing Before Office Hysterosocpy: a Randomized Controlled Trial [NCT02713074]Phase 3147 participants (Actual)Interventional2016-10-31Completed
Povidone Iodine 5% Eye Wash in Treatment of Epidemic Keratoconjunctivitis [NCT04169919]350 participants (Actual)Interventional2014-11-30Completed
Povidone-iodine vs. Chlorhexidine Gluconate - A Comparison of Surgical Preparations and Wound Infection Rates for Elective Cesarean Sections [NCT00528008]Phase 3268 participants (Actual)Interventional2007-12-31Terminated(stopped due to Study was stopped following interim analysis.)
Comparative Study of Two Antiseptics Solutions for the Prevention of Surgical Site Infection [NCT00692757]Phase 2432 participants (Anticipated)Interventional2008-07-31Recruiting
Randomized Phase II Study of Recombinant Human Epidermal Growth Factor (rhEGF) on Oral Mucositis Induced by Intensive Chemotherapy for Hematologic Malignancies [NCT00845819]Phase 2138 participants (Actual)Interventional2009-02-28Completed
Prospective Randomized Double Blind Study Comparing the Effect of Oropharyngeal Decontamination by Povidone-iodine to Placebo on Ventilator-associated Pneumonia in Patients With Head Trauma or Cerebral Hemorrhage [NCT00950027]Phase 3179 participants (Actual)Interventional2008-04-30Terminated
Chlorhexidine-Alcohol Versus Povidone-Iodine for Surgical-Site Antisepsis:A Prospective, Randomized, Multicenter Clinical Trial [NCT00290290]Phase 3849 participants (Actual)Interventional2003-09-30Completed
May Betadine Improve Cesarean Section Outcomes? [NCT02865993]80 participants (Actual)Interventional2015-09-30Completed
Comparison of Effectiveness of Povidone-iodine Versus Saline Versus 3M Skin and Nasal Antiseptic 5% Povidone-Iodine USP Swabs for Decolonizing Intranasal MSSA/MRSA [NCT02652325]0 participants InterventionalActive, not recruiting
Povidone-iodine 2% Eye Drop Versus Artificial Tear Drop for Treatment of Adenoviral Keratoconjunctivitis [NCT04041856]Phase 1/Phase 2200 participants (Anticipated)Interventional2019-08-23Not yet recruiting
Comparison of the Effectiveness of Povidone-Iodine Alone to Povidone-Iodine-Tetracycline Combination for Chemical Pleurodesis in Malignant Pleural Effusion [NCT04039126]Phase 162 participants (Anticipated)Interventional2019-06-20Recruiting
A Topical Antiseptic Bundle for Decreasing Surgical Site Infection in Head and Neck Cancer Patients: Perioperative Effects on the Oral Microbiome [NCT04721626]25 participants (Actual)Observational2021-01-06Completed
Mouth Rinses Efficacy on Salivary SARS-CoV-2 Viral Load: A Randomized Clinical Trial [NCT04721457]Phase 490 participants (Actual)Interventional2021-01-03Completed
The Efficacy of 2% Chlorhexidine Gluconate in 70% Alcohol Compared With 10% Povidone Iodine in Reducing Blood Culture Contamination in Pediatric Patients [NCT01919593]Phase 41,269 participants (Actual)Interventional2012-01-31Completed
A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers [NCT00386958]Phase 2172 participants Interventional2002-11-30Completed
Topical Umbilical Cord Care for the Prevention of Colonization and Invasive Infections [NCT01886001]53 participants (Actual)Interventional2012-11-30Completed
Comparative Efficacy of Two Different Regimens of Povidone-iodine 5% Eye Drops Instillation in Reducing Conjunctival Bacterial Flora [NCT01739920]Phase 4124 participants (Actual)Interventional2011-05-31Completed
To Determine the Difference in Positive Bacterial Cultures in Cesarean Sections With 2% Chlorhexidine- Gluconate, 70% Isopropyl Alcohol (Chloraprep) vs. Povidone-iodine 10% (Betadine) Preoperative Surgical Scrub [NCT01975805]60 participants (Actual)Interventional2010-01-31Completed
Does Chlorhexidine and/or Betadine Prep Thoroughly Clean the Surgical Sites and Fingernails in Pediatric Arm Surgery Following Trauma? [NCT04225065]Phase 420 participants (Anticipated)Interventional2020-06-17Recruiting
A Randomised Control Trial to Determine Whether a 5 Day Course of Antibiotics is More Clinically and Cost Effective Than a 24 Hour Prophylactic Course for the Prevention of Surgical Site Infection Following Lower Limb Amputation [NCT02018094]Phase 4160 participants (Actual)Interventional2013-10-08Completed
Chlorhexidine-Alcohol Vs. Povidone-Iodine for Prevention of Surgical Site Infection After Cesarean Delivery: A Randomized Trial [NCT02027324]0 participants (Actual)Interventional2015-06-30Withdrawn(stopped due to Another study with similar methods was recently published)
Comparison of Normal Saline, Hydrogen Peroxide, Chlorhexidine and Povidone-Iodine Mouth Rinses in COVID-19 Patients [NCT04603794]Phase 460 participants (Anticipated)Interventional2020-10-01Recruiting
Study to Investigate if Sucking a Coldamaris Lozenge Elutes Sufficient Iota-carrageenan to Inactivate Usual Common Cold Viruses [NCT04533906]29 participants (Actual)Interventional2020-08-04Completed
Effects of Ultrasonic Debridement With PVP-iodine Irrigation on Post-treatment Bacteraemia Compared to Ultrasonic Debridement With Water [NCT01647347]Phase 420 participants (Actual)Interventional2012-08-31Completed
Pain Control and Subconjunctival Hemorrhage Size After Intravitreal Injection Using Cooled Anesthetic Eye Drops and Antiseptics: A Double-Blind Randomized Controlled Trial [NCT04827836]100 participants (Actual)Interventional2021-07-11Completed
Povidone Iodine vs AVEnova: A Pre-injection Disinfection Study (PAVE Study) [NCT04018482]Phase 450 participants (Actual)Interventional2019-07-16Completed
Effect of Nasal and Oropharyngeal Use of Povidone Iodine and Glycyrrhizin on Ventilator-associated Respiratory Infections: A Randomized Trial [NCT05895773]Phase 2/Phase 378 participants (Actual)Interventional2023-06-24Completed
Comparison of Conjunctival Antimicrobial Activity and Patient Comfort Between Topical Hypochlorous Acid (Avenova) and Betadine [NCT04981860]Phase 4230 participants (Anticipated)Interventional2021-08-06Recruiting
Antiseptic Preparation of the Rectum Prior to Transrectal Prostate Biopsy [NCT00999427]865 participants (Actual)Interventional2009-10-31Completed
Preoperative Vaginal Cleansing With Povidone Iodine and the Risk of Post Cesarean Endometritis [NCT02693483]Phase 4306 participants (Anticipated)Interventional2015-04-30Recruiting
Efficacy of Iodopovidone Versus Talc in Palliative Malignant Pleural Effusion: a Randomized Controlled Trial Study [NCT02674243]Phase 360 participants (Actual)Interventional2015-11-30Completed
Efficacy of Gastrostomy Tube Coated With Povidone-iodine for Reducing Peristomal Infection Rate After PEG Insertion [NCT04249570]90 participants (Anticipated)Interventional2014-04-30Enrolling by invitation
The Efficacy of Swabbing of Subcutaneous Tissues of Cesarean Section Wounds With Povidone Iodine to Prevent Postoperative Wound Infection: A Randomized Controlled Clinical Trial [NCT02868372]538 participants (Anticipated)Interventional2016-09-30Not yet recruiting
Effect of Chlorhexidine Gluconate Versus Povidone-iodine on the Vaginal Microbiome as Vaginal Operative Preparation During Gynecologic Surgeries [NCT04658355]100 participants (Anticipated)Interventional2020-12-15Not yet recruiting
A Randomized Trial of Vaginal Prep Solutions to Reduce Bacteria Colony Counts in Patients Having a Vaginal Surgery [NCT03854370]35 participants (Actual)Interventional2019-06-21Suspended(stopped due to COVID impact on recruitment; challenges with enrollment)
Chlorhexidine Gluconate vs Povidone-Iodine Vaginal Cleansing Solution Prior to Cesarean Delivery: A Randomized Comparator Controlled Trial [NCT02915289]Phase 31,114 participants (Actual)Interventional2016-12-31Completed
Comparison of Chlorhexidine Gluconate and Povidone Iodine as a Preoperative Antisepsis in Clean-contaminated Abdominal Surgery : a Randomized Prospective Trial [NCT01495117]Phase 3534 participants (Actual)Interventional2011-10-31Completed
A Randomised, Blinded Study to Assess the Effect of Betadine in the Groin Wound of Patients Undergoing Primary Varicose Vein Surgery [NCT00500669]Phase 360 participants (Actual)Interventional2004-06-30Terminated(stopped due to Recruitement too slow)
A Clinical Trial of the Treatment of Fungal Corneal Ulcers With Povidone-Iodine [NCT00516399]Phase 378 participants (Actual)Interventional2008-03-31Terminated(stopped due to The DSMC decided it appeared futile to attempt to demonstrate non-inferiority of povidone-iodine to Natamycin.)
Povidone-Iodine Intranasal for Prophylaxis in Front-line Health-care Personnel and Inpatients During the Sars-CoV-2 Pandemic [NCT04364802]Phase 298 participants (Actual)Interventional2020-04-29Completed
Mitigating Effect of Bioaerosols During Orthodontic Procedures: A Randomized Controlled Trial [NCT05468099]40 participants (Anticipated)Interventional2022-03-29Recruiting
A Randomized, Double-Masked Trial of Topical Dexamethasone 0.1%/Povidone-iodine 0.4% Versus Artificial Tears for Treatment of Viral Conjunctivitis [NCT01481519]Phase 3100 participants (Anticipated)Interventional2011-12-31Completed
Povidone Iodine 10% Versus 7.5% Hand Scrub and Cesarean Section Wound Infections: A Randomized Trial [NCT01700803]Phase 33,231 participants (Actual)Interventional2012-01-31Completed
Vaginal Cleansing at Cesarean Delivery to Reduce Infection: A Randomized, Controlled Trial [NCT00386477]300 participants (Actual)Interventional2006-09-30Terminated(stopped due to Difficulty recruiting)
A Phase 4 Study to Evaluate Nasopharyngeal SARS-CoV-2 Viral Shedding After Halodine Nasal Antiseptic in Patients With COVID-19 [NCT04517188]Phase 440 participants (Anticipated)Interventional2021-04-01Not yet recruiting
Phase I/II Trial (Safety and Dosing) of Povidone-iodine (PVP-I) Nasal Swab For Preventing COVID-19 Spread in Healthy Subjects [NCT04510402]Phase 1/Phase 250 participants (Anticipated)Interventional2020-08-31Not yet recruiting
Project PROTECT: Protecting Nursing Homes From Infections and Hospitalization [NCT03118232]Phase 413,952 participants (Actual)Interventional2017-04-03Completed
Intranasal Povidone Iodine (PVI) to Prevent Staphylococcus Aureus Surgical Site Infections After Operative Procedures to Fix High-Energy Lower Extremity Fractures (POTENT Study) [NCT05763602]Phase 42,000 participants (Anticipated)Interventional2022-09-15Recruiting
Efficacy Comparison of Two Vaginal Solutions for Preoperative Use in Candidate Women for Vaginal Surgeries [NCT03014778]Phase 470 participants (Anticipated)Interventional2017-01-01Recruiting
A Comparative Study of the Safety and Efficacy of Face Talc Slurry and Iodopovidone for Pleurodesis [NCT00430664]100 participants Interventional2006-01-31Recruiting
Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine [NCT01313182]Phase 41,874 participants (Actual)Interventional2011-03-31Completed
Feasibility of Pre-operative Povidone Iodine Decolonization Among Orthopedic Trauma Surgery Patients To Reduce Staphylococcus Aureus Surgical Site Infections [NCT04146116]Phase 465 participants (Actual)Interventional2020-02-19Completed
Povidone-Iodine Rinses as an Adjuvant Therapy Post-Operatively: A Double-Blind Randomized Controlled Trial [NCT04278950]100 participants (Anticipated)Interventional2020-02-10Not yet recruiting
Suture Contamination Rate in Adjustable Suture Strabismus Surgery [NCT02424357]65 participants (Actual)Interventional2015-07-31Completed
Dental Office Prevention Strategies for Children: 10% Povidone Iodine (PI) Cleansing Prior to Fluoride Varnish (FV) Application [NCT02004990]12 participants (Actual)Interventional2014-01-31Completed
Nitrous Oxide for Pain Management of Intrauterine Device Insertion [NCT02391714]80 participants (Actual)Interventional2013-10-31Completed
Bacterial Wound Contamination Prior to Closure: Povidone-Iodine Versus Saline Irrigation in Pediatric Spine Fusion Surgery [NCT02527512]Phase 4173 participants (Actual)Interventional2017-07-13Completed
Can a Sinus Rinse and Mouth Wash Reduce Viral Load in COVID-19 Positive Individuals and Their Co-residents? [NCT04393792]Phase 140 participants (Anticipated)Interventional2020-05-05Recruiting
Checklist to Prevent MRSA Surgical Site Infections [NCT02216227]1,794 participants (Actual)Interventional2014-04-01Completed
The Effect of Skin Antisepsis After Primary Skin Closure on the Incidence of Surgical Site Infection After Abdominal Surgery for Sepsis: a Preliminary Report of a Randomized Controlled Trial [NCT05896462]37 participants (Actual)Interventional2019-08-19Completed
Exploring the Impact of Nasal Povidone Iodine for Prevention of Intraoperative Spread of SARS-CoV-2 Nucleic Acid Particles and Assessment of Infectivity of Transmitted Particles [NCT05745467]Phase 40 participants (Actual)Interventional2024-07-03Withdrawn(stopped due to Wouldn't be able to get enough patients. Never started the study. Suspended the IRB form.)
Role of NaSo-oropHaryngeal Antiseptic dEcolonizaiton to Reduce Covid-19 Viral Shedding and Disease Transmission: SHIELD Study [NCT04478019]Early Phase 1245 participants (Actual)Interventional2020-07-07Completed
[NCT00335088]Phase 3500 participants (Anticipated)Interventional2006-06-30Recruiting
Comparison of the Effect of Water and Soap Irrigation With With Povidone-iodine And Normal Salin Treatment of Patients With Ununion Laparatomy or Episiotomy Wound ( a Pilot Study) [NCT01619137]40 participants (Anticipated)Interventional2011-08-31Recruiting
Conjunctival Flora Patterns After Serial Intravitreal Injections Without Postinjection Topical Antibiotics in Diabetic Patients [NCT02337972]50 participants (Anticipated)Interventional2015-01-31Recruiting
Comparison of Alcoholic Chlorhexidine 2% Versus Alcoholic Povidone Iodine for Infections Prevention With Cardiac Resynchronization Therapy Device Implantation [NCT01841242]Phase 42,276 participants (Actual)Interventional2013-04-23Completed
The Effect of Dilute Chlorhexidine Versus Betadine on Microbial Growth in Operative Splash Basins During Total Joint Arthroplasty: A Prospective Clinical Trial [NCT04274517]30 participants (Actual)Interventional2021-01-16Terminated(stopped due to Preliminary analysis showed lack of positive finding, indicating a substantial number of subjects required, which is not feasible based on budget and timeline.)
A Pilot Study to Evaluate Efficacy and Safety of Hydrophilic Polyurethane Foam Dressing in Patients With Pressure Ulcer [NCT02863263]5 participants (Actual)Interventional2016-07-29Terminated(stopped due to Difficulties in meeting recruitment target)
A Pilot, Open-Labelled, Randomised Controlled Trial Of Povidone-Iodine Vs Essential Oil And Tap Water Gargling For COVID-19 Patients [NCT04410159]Phase 220 participants (Actual)Interventional2020-06-22Completed
The Antiseptic Outcome of Traditional Hand Scrubbing Versus Hand Rubbing in Surgical Room [NCT02294604]236 participants (Actual)Interventional2015-04-30Completed
A Randomized Trial of Betadine Bladder Irrigations vs. Standard of Care Prior to Indwelling Catheter Removal to Reduce Bacteriuria and Catheter-Associated Urinary Tract Infections [NCT03447639]Phase 43 participants (Actual)Interventional2018-03-29Terminated(stopped due to Lack of Patient Enrollment)
Efficacy of Povidone-Iodine Instillation Via Tunneled Pleural Catheters in Achieving Pleurodesis: A Randomized Controlled Trial [NCT02975921]Phase 40 participants (Actual)Interventional2018-07-31Withdrawn(stopped due to The site decided not to proceed with the protocol.)
[NCT01437228]Phase 4668 participants (Actual)Interventional2010-10-31Completed
Outcomes of High-volume Saline Irrigation VS Povidone-Iodine Solution Cleaning of Intraoperative Incision Wound in Preventing Surgical Site Infections in Emergency Laparotomies: A Randomized Controlled Trial [NCT05989386]Phase 2/Phase 3200 participants (Anticipated)Interventional2023-04-29Recruiting
Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With SARS-CoV-2 [NCT04371965]Phase 224 participants (Actual)Interventional2020-09-01Completed
Blood Culture Contamination: A Cluster-randomized Cross-over Trial Evaluating the Comparative Effectiveness of Three Skin Antiseptic Interventions [NCT01216761]3,879 participants (Actual)Interventional2008-05-31Completed
Aqueous-PREP: A Pragmatic Randomized Trial Evaluating Pre-operative Aqueous Antiseptic Skin Solutions in Open Fractures [NCT03385304]Phase 41,638 participants (Actual)Interventional2018-04-08Completed
A Comparison Between Povidone-iodine and Normal Saline Solution in Preoperative Vaginal Cleansing in Laparoscopic Surgery: a Randomized Clinical Study [NCT02591251]Phase 2100 participants (Actual)Interventional2015-10-31Completed
Effect of Vaginal Cleaning Using Povidone Iodine Before CS to Reduce Postoperative Wound Infection [NCT05021315]Phase 3800 participants (Anticipated)Interventional2021-09-15Recruiting
Optimizing Preoperative Disinfection of Eyes [NCT04745663]Phase 4150 participants (Actual)Interventional2021-02-08Terminated(stopped due to Not the expected 2/3 but only 1/3 of conjunctiva samples got bacterial growth. Lack of resources to keep the study going with more participants and over a considerably longer time than anticipated.)
Comparison of Antimicrobial Activity of AvenovaTM as a Sterile Skin Preparation in Humans [NCT02990013]Early Phase 121 participants (Actual)Interventional2018-12-01Completed
Evaluating XPERIENCE™ Advanced Surgical Irrigation on Risk of Periprosthetic Joint Infection: A Multicenter Randomized Controlled Trial [NCT05543941]7,600 participants (Anticipated)Interventional2023-01-02Not yet recruiting
Impact of Blood Culture Positivity Time on Clinical Management of Pediatric ICU Patients [NCT05507957]120 participants (Anticipated)Observational2023-01-01Not yet recruiting
Effectiveness of Continuous Application of Lidocaine Cream, Povidone Iodine Cream, and Honey on Second-degree Perineal Tear Healing, a Randomized Controlled Clinical Trial [NCT05946005]Phase 4200 participants (Actual)Interventional2021-12-01Completed
The Use of Diluted Povidone Iodine Irrigation in Spine Surgery [NCT01577524]Phase 258 participants (Actual)Interventional2012-01-31Terminated(stopped due to We had very low recruitment rates that would have resulted in several years being added to the study to achieve an appropriate sample size.)
Effectiveness of Hyaluronic Acid in Postoperative Cures in Partial Matriceptomes With the Phenol/Alcohol Technique. Randomized Clinical Trial [NCT04812457]Early Phase 170 participants (Actual)Interventional2021-03-06Completed
Does Povidone-Iodine on Nail Affect Pulse Oximeter Reading? [NCT05704959]122 participants (Actual)Interventional2022-03-15Active, not recruiting
Umbilical Cord Care for the Prevention of Colonization [NCT01893060]100 participants (Anticipated)Interventional2013-07-31Recruiting
Influence of Esophageal Washout on Local Carcinoma Recurrence After Curative Resection - a Randomized Controlled Trial [NCT02676791]80 participants (Actual)Interventional2016-02-16Completed
A Prospective Single-blind Placebo-controlled Trial to Establish the Efficacy and Tolerability of 10% Povidone-Iodine for Nasal S. Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA) Decolonization Among Patients Undergoing Same-day Surgery [NCT05529173]Phase 4170 participants (Anticipated)Interventional2022-09-06Recruiting
Treatment of Tracheostomy Granulomas [NCT02116608]Phase 426 participants (Actual)Interventional2014-09-30Completed
The Efficacy of Topical Povidone-Iodine Rinses in the Management of the Coronavirus Disease 2019 (COVID-19) [NCT04449965]Early Phase 15 participants (Actual)Interventional2021-01-19Terminated(stopped due to The site struggled with patient recruitment as we were not able to reach patients with COVID-19)
Tolerance of Chlorhexidine Gluconate Versus Povidone Iodine Vaginal Cleansing Solution: a Randomized Control Trial [NCT03305159]Phase 4134 participants (Actual)Interventional2017-08-01Completed
Investigating the Therapeutic Role of Topical Medical Treatment in Oral and Nasal Cavities on the Patients With Positive Severe Cute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection [NCT05049213]Phase 47 participants (Actual)Interventional2022-06-24Completed
A Phase II, Randomized, Open-label, Single-institution Study of the Effects of Povidone Iodine Oral Gargles and Nasal Rinses on Viral Load in Patients With COVID-19 [NCT04344236]Phase 20 participants (Actual)Interventional2020-04-09Withdrawn(stopped due to This study was withdrawn by the institution to minimize risk to patients and staff with regard to COVID-19.)
Povidone-iodine to Stop Access-related Infections and Transmission of Staphylococcus Aureus (PAINTS) [NCT04210505]Phase 4302 participants (Actual)Interventional2020-09-29Active, not recruiting
Reducing Adenoviral Patient Infected Days [NCT02472223]28 participants (Actual)Interventional2015-03-23Completed
Reducing Microbial Levels in High Caries Risk Adults [NCT03062605]Phase 348 participants (Actual)Interventional2011-05-21Completed
A Clinical Simulation Study of a Test Material on the Anterior Nares [NCT05617729]50 participants (Actual)Interventional2022-03-07Completed
Skin and Soft Tissue Infection (SSTI) Study [NCT02600871]Phase 4101 participants (Actual)Interventional2015-12-31Completed
Comparison the Influence of the Povidone-iodine or the Normal Saline Cleaning the Incision for the Incidence of the Surgical Site Infections for Gastric Cancer Patients With Gastrectomy- Randomized Controlled Trial [NCT02436395]340 participants (Anticipated)Interventional2015-05-31Recruiting
A Randomized, Open Label, Two Phase Trial, to Assess Various Antimicrobial Techniques for Reducing Bacterial Load Prior PrePex Removal [NCT02391077]Phase 133 participants (Anticipated)Interventional2015-04-30Not yet recruiting
Chlorhexidine Versus Povidone-iodine Antisepsis for Reduction of Post Cesarean Section Surgical Site Infection Rate:a Randomized Controlled Trial [NCT02396329]Phase 2410 participants (Anticipated)Interventional2014-06-30Recruiting
Establishment of Clinical Practice Guideline to Prevent Puerperal / Perinatal Infection in Vaginal Delivery for Pregnant Women and Newborns [NCT05122169]4,140 participants (Anticipated)Interventional2021-12-31Not yet recruiting
A Prospective Randomized Trial of Povidone-iodine Suppository Before Transrectal Ultrasound Guided Prostate Biopsy [NCT02245334]Phase 41,578 participants (Anticipated)Interventional2014-10-31Not yet recruiting
Comparison of the Effectiveness of Povidone-iodine in Reducing Conjunctival Bacterial Load Prior to Cataract Surgery in Patients Treated With a Lidocaine Gel Dilating Formulation Versus Eye Drops: A Randomized Controlled Trial [NCT01898728]101 participants (Actual)Interventional2012-12-31Completed
The Effectiveness of Oral Antiseptics on the Intraoral Viral Load of SARS-CoV-2 [NCT05214196]Phase 475 participants (Actual)Interventional2021-09-01Completed
The Role of Chlorhexidine in Minimizing the Viral Load Among COVID-19 Patients: A Randomized Controlled Clinical Trial [NCT04941131]Phase 460 participants (Anticipated)Interventional2021-07-31Not yet recruiting
Preoperative Bath in Patients Submitted to Hip Arthroplasty: Randomized Clinical Trial [NCT03001102]162 participants (Actual)Interventional2015-08-31Completed
Parasitic Ulcer Treatment Trial Pilot [NCT03484507]Phase 249 participants (Actual)Interventional2018-01-01Active, not recruiting
Povidine-Iodine Effect on Nasal Mucosa Cilia in Rhinoplasty Patients [NCT04457765]Early Phase 10 participants (Actual)Interventional2021-04-30Withdrawn(stopped due to The IRB did not approve the study to be conducted at the home institution.)
Treatment of Blepharitis With Povidone-Iodine 1% : a Randomized Controlled Trial [NCT05160623]100 participants (Anticipated)Interventional2021-08-16Recruiting
Long-term StaphyloCoccus Aureus decolonizAtion in Patients on Home parenteRal nutRition: a randomIzed multicEnter tRial. [NCT03173053]63 participants (Actual)Interventional2018-02-08Terminated(stopped due to Results interim-analysis)
Effect of Vaginal Douching With Betadine Versus Non Douching Before CS for Prevention of Post Operative Infections [NCT03397615]1,200 participants (Anticipated)Interventional2019-01-03Recruiting
Vancomycin Powder and Dilute Povidone Iodine Lavage for Infection Prophylaxis in High Risk Total Joint Arthroplasty [NCT04075526]Phase 12,129 participants (Actual)Interventional2019-10-01Active, not recruiting
A Randomized Pilot Trial of Dilute Povidone-iodine Irrigation vs No Irrigation for Children With Acute, Perforated Appendicitis [NCT02664220]Phase 2100 participants (Actual)Interventional2016-04-30Completed
Comparative Study of 10% Povidone-iodine Against 10% Sodium Hypochlorite as Skin Antiseptics in Human Volunteers. [NCT00738543]Phase 348 participants (Actual)Interventional2008-08-31Completed
The Effect of Skin Cleansers on the Skin Surface Microbiome [NCT03348917]Phase 415 participants (Actual)Interventional2017-12-28Completed
Antiseptic Pleural Irrigation for Patients With Pleural Infection [NCT04761133]Phase 136 participants (Actual)Interventional2021-03-04Completed
Clinical Evaluation of Antiseptic Mouth Rinses to Reduce Salivary Viral Load of SARS-CoV-2 in COVID-19 Patients [NCT04707742]160 participants (Actual)Interventional2020-06-15Completed
Chlorhexidine-Alcohol Versus Povidone-Iodine for Surgical Site Antisepsis Prior to Cesarean Delivery [NCT02202577]932 participants (Actual)Interventional2014-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00231153 (3) [back to overview]Microbiologically-confirmed LCSI
NCT00231153 (3) [back to overview]Local Catheter Site Infection (LCSI)
NCT00231153 (3) [back to overview]Catheter Colonization (CC)
NCT00290290 (1) [back to overview]The Primary Objective of This Trial is to Compare the Impact of Disinfecting the Skin With Chloraprep vs. Betadine on the Rates of Infection of Clean-contaminated Surgical Wounds.
NCT00386477 (1) [back to overview]Number of Participants Who Experienced Composite Endometritis Plus Wound Complications.
NCT00738543 (5) [back to overview]Presence of Skin Reactions for the 10% Povidone-iodine Period
NCT00738543 (5) [back to overview]Presence af Allergy or Skin Reaction for the 10% Sodium Hypochlorite Period
NCT00738543 (5) [back to overview]Bacterial Count of Skin Cultures for the 10% Povidone-iodine Period
NCT00738543 (5) [back to overview]Bacterial Colony Forming Units for the Control Period
NCT00738543 (5) [back to overview]Bacterial Colony Forming Units for the 10% Sodium Hypochlorite Period
NCT01216761 (1) [back to overview]Blood Culture Contamination
NCT01313182 (2) [back to overview]Measure Rate of Staphylococcus Aureus Resistance to Mupirocin.
NCT01313182 (2) [back to overview]Surgical Site Infections Occurring Within 12 Months of Surgical Procedure
NCT02004990 (2) [back to overview]Dental Plaque Composition Measured by Numbers of Bacteria Present
NCT02004990 (2) [back to overview]Dental Plaque Levels Measures on Scale of 0-2
NCT02116608 (2) [back to overview]Success and Failure Rates for Each Treatment Method
NCT02116608 (2) [back to overview]Categorical Improvement (Degree of Improvement)
NCT02202577 (2) [back to overview]Number of Patients With Surgical Site Infection
NCT02202577 (2) [back to overview]Number of Patients With Non-infections Surgical Site Complications
NCT02294604 (4) [back to overview]Duration of Hand Washing
NCT02294604 (4) [back to overview]Microorganisms on Hands After Scrubbing
NCT02294604 (4) [back to overview]Microorganisms on Hands After Surgery
NCT02294604 (4) [back to overview]Microorganisms on Hands Before Scrubbing
NCT02391714 (3) [back to overview]Baseline Mean Pain Scores
NCT02391714 (3) [back to overview]Patient Satisfaction With Over-all Pain Control With IUD Insertion - VAS
NCT02391714 (3) [back to overview]Mean Maximum Procedural Pain Scores
NCT02424357 (3) [back to overview]Reduction of Contamination Rate Using Post-operative 5% Povidone Iodine
NCT02424357 (3) [back to overview]Suture Colonization Rate in Adjustable Suture Strabismus Surgery
NCT02424357 (3) [back to overview]Identification of Bacterial Species Cultured From Suture Material
NCT02472223 (2) [back to overview]Participant Reported Bothersomeness of Ocular Symptoms
NCT02472223 (2) [back to overview]Percent Change From Peak Viral Load
NCT02527512 (2) [back to overview]Culture Positivity
NCT02527512 (2) [back to overview]Risk Groups
NCT02600871 (3) [back to overview]Number of Participants With a Clinical Cure
NCT02600871 (3) [back to overview]Infection Rates of Household Contacts
NCT02600871 (3) [back to overview]Rate of New Lesion Development
NCT02664220 (4) [back to overview]Number of Participants Who Were Readmitted to the Hospital
NCT02664220 (4) [back to overview]Number of Participants With Postoperative Intra-abdominal Abscess
NCT02664220 (4) [back to overview]Total Hospital Length of Stay
NCT02664220 (4) [back to overview]Number of Participants Who Visited the Emergency Room
NCT02863263 (7) [back to overview]Safety as Evaluated by Number of Local Adverse Events at the Target Pressure Ulcer
NCT02863263 (7) [back to overview]Number of Participants With a Dressing Change Frequency Greater Than Twice Per Week
NCT02863263 (7) [back to overview]Number of Patients With Complete Healing of Ulcer Within 12 Weeks
NCT02863263 (7) [back to overview]Number of Participants With New Infections at the Pressure Ulcer Based on Clinical Signs and Symptoms Checklist (CCSC)
NCT02863263 (7) [back to overview]Number of Patients Achieving Early Study Completion Due to Complete Healing
NCT02863263 (7) [back to overview]Pressure Ulcer Scale for Healing (PUSH) Score Measured Using PUSH Tool Version 3.0 At Week 12
NCT02863263 (7) [back to overview]Pressure Ulcer Size Measured Using A Ruler at Week 12
NCT03062605 (1) [back to overview]Microbial Levels
NCT03101371 (6) [back to overview]Number of Participants With Extended Hospital Stay Due to a Urinary Tract Infection (UTI)
NCT03101371 (6) [back to overview]Number of Participants With Closed Drainage System Disrupted During Placement of Catheter
NCT03101371 (6) [back to overview]Number of Participants With a Catheter Associated Urinary Tract Infection (CAUTI)
NCT03101371 (6) [back to overview]Number of Participants That Were Readmitted, Had Additional Clinic Visits or Went to the Emergency Department (ED) for Any Reason
NCT03101371 (6) [back to overview]Average Patient Satisfaction
NCT03101371 (6) [back to overview]Number of Patients That Used Antibiotics at the Time of Surgery and Post-surgery
NCT03118232 (3) [back to overview]Hospital Transfers Due to Infection
NCT03118232 (3) [back to overview]All Hospital Transfers
NCT03118232 (3) [back to overview]Multidrug-resistant Organism (MDRO) Colonization (Secondary Manuscript)
NCT03305159 (1) [back to overview]Number of Participants With Vaginal or Urinary Symptoms After Surgery, Assessed by Validated Questionnaire (Modified PRO-CTCAE)
NCT03385304 (3) [back to overview]Number of Participants With a Deep Incisional or Organ/Space Infection
NCT03385304 (3) [back to overview]Number of Participants With a Superficial Incisional Surgical Site Infection (SSI)
NCT03385304 (3) [back to overview]Number of Participants With an Unplanned Fracture-Related Reoperation
NCT03638947 (2) [back to overview]Identify the Number of Preoperative Patients Positive for S. Aureus Using Collection Kits
NCT03638947 (2) [back to overview]Quantitate the Reduction of S. Aureus Tranmission
NCT04146116 (3) [back to overview]Number of Participants With Surgical Site Infection
NCT04146116 (3) [back to overview]Number of Participants With Staphylococcus Aureus Nasal Colonization
NCT04146116 (3) [back to overview]Number of Participants With Staphylococcus Aureus Nasal Colonization
NCT04347954 (10) [back to overview]Count of Participants Experiencing Fevers as a Measure of Frequency of Symptoms Related to SARS-CoV-2
NCT04347954 (10) [back to overview]Count of Participants Experiencing Fatigue as a Measure of Frequency of Symptoms Related to SARS-CoV-2
NCT04347954 (10) [back to overview]Count of Participants Experiencing Chills as a Measure of Frequency of Symptoms Related to SARS-CoV-2
NCT04347954 (10) [back to overview]Count of Participants Experiencing Adverse Events of Interest After Nasal Sprays
NCT04347954 (10) [back to overview]Mean Cycle Threshold (Ct) Values Through Day 3 as a Measure of Change in Viral Titers of SARS-CoV-2
NCT04347954 (10) [back to overview]Count of Participants Normosmia, Microsmia, or Anosmia as a Measure of Change in the University of Pennsylvania Smell Identification Test (UPSIT)
NCT04347954 (10) [back to overview]Count of Participants Experiencing Sore Throat as a Measure of Frequency of Symptoms Related to SARS-CoV-2
NCT04347954 (10) [back to overview]Count of Participants Experiencing Nasal Congestion as a Measure of Frequency of Symptoms Related to SARS-CoV-2
NCT04347954 (10) [back to overview]Count of Participants Experiencing Loss of Sense of Taste as a Measure of Frequency of Symptoms Related to SARS-CoV-2
NCT04347954 (10) [back to overview]Count of Participants Experiencing Loss of Sense of Smell as a Measure of Frequency of Symptoms Related to SARS-CoV-2
NCT04364802 (5) [back to overview]PVP-I Ease of Use
NCT04364802 (5) [back to overview]PVP-I Comfort
NCT04364802 (5) [back to overview]Percent of Patients Testing Positive for COVID-9.
NCT04364802 (5) [back to overview]Percent of Healthcare Workers Testing Positive for COVID-19.
NCT04364802 (5) [back to overview]Percent of Community Participants Testing Positive for COVID-9.
NCT04410159 (5) [back to overview]Number of Participants With Early Viral Clearance
NCT04410159 (5) [back to overview]Number of Participants With Negative RT-PCR Results
NCT04410159 (5) [back to overview]Number of Patients That Progress to More Severe Disease
NCT04410159 (5) [back to overview]Number of Patients With Abnormal Laboratory Findings
NCT04410159 (5) [back to overview]Number of Patients With Abnormal Radiological Findings

Microbiologically-confirmed LCSI

MCLCSI is a subset of EC-adjudicated LCSI for any catheter where there is (1) growth of a recognized pathogen from a culture or any purulence or exudate from the same insertion site, or (2) a positive culture of the subcutaneous segment of the catheter meeting criteria for significant colonization. (NCT00231153)
Timeframe: study completion

InterventionEvents (Number)
Omiganan 1% Gel31
Povidone-Iodine62

[back to top]

Local Catheter Site Infection (LCSI)

LCSI was defined as a study catheter showing any 2 of the following criteria: erythema >= 2; edema >= 2; presence of purulence, pain, or abnormal study catheter site warmth. In addition, an action must have been taken that indicated a LCSI was present. (NCT00231153)
Timeframe: study completion

InterventionEvents (Number)
Omiganan 1% Gel50
Povidone-Iodine70

[back to top]

Catheter Colonization (CC)

CC was defined as a positive culture of any catheter segment >= 15 CFU (roll-plate method) or >999 CFU/ml (sonication method) or a positive blood culture drawn via the catheter where the time-to-positivity difference of catheter line vs. peripheral blood >120 minutes (catheter positive first). (NCT00231153)
Timeframe: study completion

InterventionEvents (Number)
Omiganan 1% Gel369
Povidone-Iodine478

[back to top]

The Primary Objective of This Trial is to Compare the Impact of Disinfecting the Skin With Chloraprep vs. Betadine on the Rates of Infection of Clean-contaminated Surgical Wounds.

The primary end point of the study was the occurrence of any surgical-site infection. Diagnosis of surgical-site infection was diagnosed by a blinded reviewer following criteria developed by the Center for Disease Control. The significance of difference between the two study groups in terms of patient characteristics was determined with the use of the Wilcoxon rank-sum test for continuous variables and Fisher's exact test for categorical variables. For efficacy outcomes, we compared the proportions of patients in the two study groups who could be evaluated and who any type of surgical-site infection using Fisher's exact test and calculating the relative risk of infection and 95% confidence intervals. To determine whether the results were consistent across the 6 participating hospitals, a prespecified Breslow-Day test for homogeneity was performed. (NCT00290290)
Timeframe: during surgery and within the 30 days post surgery

InterventionPercentage of Post Operative Infections (Number)
Povidone-Iodine16.1
Chlorhexidine-Alcohol9.5

[back to top]

Number of Participants Who Experienced Composite Endometritis Plus Wound Complications.

Endometritis was diagnosed clinically as uterine pain and fever requireing antibiotics. Wound complications included wound infection, seroma, hematoma, or separation. (NCT00386477)
Timeframe: 1 month

Interventionparticipants (Number)
Vag Prep10
Control17

[back to top]

Presence of Skin Reactions for the 10% Povidone-iodine Period

Presence of allergy or any skin reaction at 24 hours after the antiseptic application (NCT00738543)
Timeframe: 24 hours

InterventionNumber of participants with skin reactio (Number)
Whole Group0

[back to top]

Presence af Allergy or Skin Reaction for the 10% Sodium Hypochlorite Period

Presence of allergy or skin reaction at 24 hours after the application of the antiseptic (NCT00738543)
Timeframe: 24 hours

InterventionNumber of participants with reaction (Number)
Whole Group0

[back to top]

Bacterial Count of Skin Cultures for the 10% Povidone-iodine Period

Bacterial colony count of skin cultures to determine antiseptic properties (NCT00738543)
Timeframe: 24 hours

InterventionColony-forming units per cm squared (Median)
Whole Group231

[back to top]

Bacterial Colony Forming Units for the Control Period

After incubation, the outcome assessor counted the colonies to determine the colony-forming units per square centimeter (CFU/cm2) of skin. (NCT00738543)
Timeframe: 24 hours

InterventionColony-forming units per cm squared (Median)
Whole Group1500

[back to top]

Bacterial Colony Forming Units for the 10% Sodium Hypochlorite Period

After incubation, the outcome assessor counted the colonies to determine the colony-forming units per square centimeter (CFU/cm2) of skin. (NCT00738543)
Timeframe: 24 hours

InterventionColony-forming units per cm squared (Median)
Whole Group192

[back to top]

Blood Culture Contamination

A culture set was considered contaminated if it yielded growth of typical skin contaminants including aerobic gram positive rods, Lactobacillus sp, Propionibacterium acnes, Micrococcus sp, Bacillus sp (not B. anthracis or B. cereus), coag negative Staphylococcus, Neisseria sp (not N. meningitides or N. gonorrhoeae), or gamma-hemolytic streptococci (not Enterococcus sp) from only 1 of 2 or more blood culture sets obtained from different sites. (NCT01216761)
Timeframe: 5 days

Interventionblood culture sets (Number)
Chlorhexidine Gluconate (CHG_41
Iodine Tincture (IT)32
Povidone Iodine (PI)25

[back to top]

Measure Rate of Staphylococcus Aureus Resistance to Mupirocin.

Lab cultured isolates - they will measure rate of Staphylococcus aureus resistance to mupirocin. Both arms were sampled and tested post-op. (NCT01313182)
Timeframe: Isolates collected and frozen immediately post-surgery.

InterventionParticipants (Count of Participants)
3M Skin and Nasal Antiseptic21
Bactroban Nasal24

[back to top]

Surgical Site Infections Occurring Within 12 Months of Surgical Procedure

Measure the rate (number and percent of patients) with deep and superficial surgical site infections after primary orthopedic surgery and primary spinal fusion surgery requiring implantation of prosthetic material. (NCT01313182)
Timeframe: 12 months

Interventionparticipants (Number)
3M Skin and Nasal Antiseptic0
Bactroban Nasal5

[back to top]

Dental Plaque Composition Measured by Numbers of Bacteria Present

Dental plaque is a multispecies bacterial biofilm and the specific bacteria populating this biofilm will be measured. Measurement will be change in thickness of the biofilm (NCT02004990)
Timeframe: 2-4 weeks

Interventionmicrometers (Mean)
Single Cleansing Procedure of 10% Povidone Iodine Cleansing1.25

[back to top]

Dental Plaque Levels Measures on Scale of 0-2

Modified plaque index for the mixed dentition scale is 0-2 (0=best 2=worse) (NCT02004990)
Timeframe: 2-4 weeks

Interventionunits on a scale (Mean)
Single Cleansing Procedure of 10% Povidone Iodine Cleansing0.391

[back to top]

Success and Failure Rates for Each Treatment Method

"Definition of success: The investigators are defining successful treatment of tracheostomy granulomas as a decrease in the frequency of granulomas over a six week observation period using the assigned treatment or partial or complete resolution of the granuloma. Partial resolution is defined as 25-75% resolution and complete resolution is defined as greater than 75% resolution.~Definition of failure: The investigators are defining a treatment as a failure if during the six week observation period of using the assigned treatment, there is either no improvement in the resolution or there has been an increase in size or frequency of tracheostomy granulomas." (NCT02116608)
Timeframe: Over 6 weeks

,,
InterventionParticipants (Count of Participants)
SuccessFailure
Group 1: Betadine63
Group 2: Hydrocortisone Butyrate Cream, 1.0%34
Group 3: Silver Nitrate52

[back to top]

Categorical Improvement (Degree of Improvement)

"Categorical success/failure data. the size of the granuloma will be measured and recorded. The percent circumference will also be measured. The approximate percent decrease in the granuloma size will be determined to determine the category subject's change in granuloma:~i. Complete resolution: >90% improvement (Score = 4) ii. Improvement: 50 - 90% improvement (Score = 3) iii. Minimal improvement: < 50% improvement (Score = 2) iv. No improvement (Score = 1) v. Worsening (Score = 0)" (NCT02116608)
Timeframe: Over 6 Weeks

,,
InterventionParticipants (Count of Participants)
WorseningNo improvementMinimal improvement: < 50% improvementImprovement: 50-90% improvementComplete resolution: >90% improvement
Group 1: Betadine01224
Group 2: Hydrocortisone Butyrate Cream, 1.0%21103
Group 3: Silver Nitrate20005

[back to top]

Number of Patients With Surgical Site Infection

Number of Patients with Cesarean-Related surgical site infection by Center for Disease Control (CDC) criteria: superficial, deep, organ space. (NCT02202577)
Timeframe: 4 weeks after cesarean delivery

InterventionParticipants (Count of Participants)
Chlorhexidine - Isopropyl Alcohol29
Povidone-Iodine Scrub and Paint33

[back to top]

Number of Patients With Non-infections Surgical Site Complications

Non-infection complications: allergic skin reactions, hematomas, wound separation, dehiscence. (NCT02202577)
Timeframe: 4 weeks after cesarean delivery

InterventionParticipants (Count of Participants)
Chlorhexidine - Isopropyl Alcohol19
Povidone-Iodine Scrub and Paint17

[back to top]

Duration of Hand Washing

The secondary outcome is the duration of hand washing (NCT02294604)
Timeframe: Immediately

InterventionMinute (Mean)
Group R3.2
Group I3.64
Group C4.8

[back to top]

Microorganisms on Hands After Scrubbing

The secondary outcomes is the colonies grown on bacterial culture plates and expressed as colony-forming units (CFU) on plates (NCT02294604)
Timeframe: 2 days after sampling

Interventioncolony forming unit (Mean)
Group R1.38
Group I4.29
Group C0.48

[back to top]

Microorganisms on Hands After Surgery

The secondary outcomes is the colonies grown on bacterial culture plate (NCT02294604)
Timeframe: 2 days after sampling

Interventioncolony forming unit (Mean)
Group R4.7
Group I3.9
Group C4.1

[back to top]

Microorganisms on Hands Before Scrubbing

The primary outcome is the colonies grown on bacterial culture plates and expressed as colony-forming units (CFU) on plates (NCT02294604)
Timeframe: 2 days after sampling

Interventioncolony forming unit (Mean)
Group R28.99
Group I38.64
Group C22.91

[back to top]

Baseline Mean Pain Scores

Baseline pain scores prior to IUD insertion is assessed using a 0-100mm VAS with anchors 0 equals no pain and 100 equals worst pain imaginable. The minimal clinically important difference in pain for this study was set at 15mm. (NCT02391714)
Timeframe: Before the IUD insertion procedure

Interventionunits on a scale (Mean)
Oxygen (Placebo)1.9
Nitrous Oxide (NO)2.4

[back to top]

Patient Satisfaction With Over-all Pain Control With IUD Insertion - VAS

Satisfaction will be measured using a 100mm Visual Analog Scale (VAS), with anchors 0mm for very satisfied and 100mm for very dissatisfied. (NCT02391714)
Timeframe: Prior to clinic discharge, which is an average of 15 minutes after the procedure

Interventionunits on a scale (Mean)
Oxygen (Placebo)60.3
Nitrous Oxide (NO)66.0

[back to top]

Mean Maximum Procedural Pain Scores

Pain is assessed using a 0-100mm VAS with anchors 0 equals no pain and 100 equals worst pain imaginable. The minimal clinically important difference in pain for this study was set at 15mm. (NCT02391714)
Timeframe: 2 minutes after the procedure.

Interventionunits on a scale (Mean)
Oxygen (Placebo)55.3
Nitrous Oxide (NO)54.3

[back to top]

Reduction of Contamination Rate Using Post-operative 5% Povidone Iodine

Comparison of suture colonization rates with and without instillation of a drop of povidone-iodine at surgery completion (NCT02424357)
Timeframe: 48 hours

Interventionrelative risk (Number)
With or Without 5% Povidone Iodine Ophthalmic Solution1.1

[back to top]

Suture Colonization Rate in Adjustable Suture Strabismus Surgery

1 cm section of the suture proximal to the knot will be harvested and placed in a tube with 2 ml of trypticase soy broth (TSB).The TSB tubes will be monitored for growth of bacteria at 48 hours (NCT02424357)
Timeframe: 48 hours

Interventionpercentage sutures positive for bacteria (Number)
5% Povidone Iodine Ophthalmic Solution57
no Povidone-iodine Ophthalmic Solution47

[back to top]

Identification of Bacterial Species Cultured From Suture Material

The collected sutures will be monitored for bacterial growth for up to 7 days. When bacterial growth is observed, 1 mL of the solution will be inoculated on chocolate, MacConkey, and anaerobic blood agars and incubated for an additional 24 to 48 hours to identify organisms and quantify growth. In vitro susceptibility patterns will be determined. (NCT02424357)
Timeframe: 7 days plus 24 to 48 hours

Interventionnumber of positive bacterial isolates (Number)
Staphylococcus epidermidisStaphylococcus lugdunensisStaphylococcus aureusStaphylococcus capitisStaphylococcus hominisPropionibacterium acnesStaphylococcus cohniiStaphylococcus warneriStaphylococcus xylosusCitrobacter koseriLactococcus lactis
With or Without 5% Povidone Iodine Ophthalmic Solution403222211111

[back to top]

Participant Reported Bothersomeness of Ocular Symptoms

Participants reported bothersomeness of ocular symptoms on a 10 point scale 0=not at all. 10=very bothersome (NCT02472223)
Timeframe: 21 days

InterventionUnit on a scale (Median)
Betadine 5%4.5
Artificial Tears8.0

[back to top]

Percent Change From Peak Viral Load

To compare efficacy of Betadine 5% to artificial tears to change from peak viral load in Adenoviral conjunctivitis (NCT02472223)
Timeframe: 21 days

InterventionPercent of peak Viral Load (Median)
Betadine 5%1.9
Artificial Tears13.2

[back to top]

Culture Positivity

Assess feasibility of a larger randomized controlled trial using significance of differences in the bacteriology and contamination rates of both treatment arms. Also measured baseline tissue colonization rates. (NCT02527512)
Timeframe: Cultures taken before and after irrigation during surgery

InterventionParticipants (Count of Participants)
pre-washout72256710pre-washout72256711post-washout72256710post-washout72256711
bacteria absentbacteria present
Povidone-Iodine14
Normal Saline13
Povidone-Iodine63
Normal Saline63
Povidone-Iodine12
Normal Saline14
Povidone-Iodine65
Normal Saline62

[back to top]

Risk Groups

Baseline (pre-irrigation) and post-irrigation tissue colonization rates and changes in culture positivity (NCT02527512)
Timeframe: Cultures taken before and after irrigation during surgery

InterventionParticipants (Count of Participants)
pre-irrigation72256713pre-irrigation72256712pre-irrigation72256714pre-irrigation72256715post-irrigation72256712post-irrigation72256713post-irrigation72256714post-irrigation72256715
positivenegative
High Risk Povidone-iodine2
High Risk Saline3
Low Risk Povidone-iodine12
Low Risk Saline10
High Risk Povidone-iodine16
High Risk Saline16
Low Risk Povidone-iodine47
Low Risk Saline47
High Risk Povidone-iodine5
High Risk Saline4
Low Risk Povidone-iodine7
High Risk Povidone-iodine13
High Risk Saline15
Low Risk Povidone-iodine52

[back to top]

Number of Participants With a Clinical Cure

Clinical cure was defined as improvement in the initial wound with respect to a decrease in measured size, erythema, and purulent discharge. Wound management at the follow up visits was left up to the discretion of the treating provider, but additional interventions for patients not clinically improving or worsening were considered a lack of clinical cure. (NCT02600871)
Timeframe: 7-10 Days

InterventionParticipants (Count of Participants)
Provodine45
Standard Care42

[back to top]

Infection Rates of Household Contacts

New lesions (abscess, pustule, carbuncle, or furuncle) that developed in household contacts of subjects within 30 days of enrollment (NCT02600871)
Timeframe: 30 Days

InterventionParticipants (Count of Participants)
Provodine2
Standard Care4

[back to top]

Rate of New Lesion Development

New lesions, defined as a new abscess, pustule, carbuncle, or furuncle at least 5cm away from the initial wound, that developed in the subject within 30 days of enrollment (NCT02600871)
Timeframe: 30 Days

InterventionParticipants (Count of Participants)
Provodine8
Standard Care8

[back to top]

Number of Participants Who Were Readmitted to the Hospital

Whether or not a patient was readmitted to the hospital within 30 days after the operation will be determined through chart review, clinical encounters, and phone calls. (NCT02664220)
Timeframe: 30 days post surgery

InterventionParticipants (Count of Participants)
Povidone-iodine Irrigation0
No Irrigation3

[back to top]

Number of Participants With Postoperative Intra-abdominal Abscess

30 days postoperative intra-abdominal abscess was confirmed by an image using a standardized definition and protocol (NCT02664220)
Timeframe: 30 days post surgery

InterventionParticipants (Count of Participants)
Povidone-iodine Irrigation6
No Irrigation8

[back to top]

Total Hospital Length of Stay

Total hospital length of stay will be the aggregate of all days in the hospital including any appendicitis-related readmissions within 30 postoperative days. (NCT02664220)
Timeframe: 30 days post surgery

Interventiondays (Mean)
Povidone-iodine Irrigation5.1
No Irrigation6.1

[back to top]

Number of Participants Who Visited the Emergency Room

Whether or not a patient visited the emergency room for care directly related to the operation within 30 days after the operation will be determined through chart review, clinical encounters, and phone calls. (NCT02664220)
Timeframe: 30 days post surgery

InterventionParticipants (Count of Participants)
Povidone-iodine Irrigation3
No Irrigation7

[back to top]

Safety as Evaluated by Number of Local Adverse Events at the Target Pressure Ulcer

Examples of these local events are erythema, edema, itching, flare and rash. (NCT02863263)
Timeframe: 12 weeks

Interventionlocal adverse events (Number)
Foam Dressing1
Foam Dressing With Povidone Iodine0

[back to top]

Number of Participants With a Dressing Change Frequency Greater Than Twice Per Week

(NCT02863263)
Timeframe: 12 weeks

Interventionparticipants (Number)
Foam Dressing3
Foam Dressing With Povidone Iodine2

[back to top]

Number of Patients With Complete Healing of Ulcer Within 12 Weeks

Complete healing is defined as epithelial tissue covering 100% of the ulcer, with intact dermis and epidermis and without abrasion or ulceration. (NCT02863263)
Timeframe: 12 weeks

InterventionParticipants (Count of Participants)
Foam Dressing0
Foam Dressing With Povidone Iodine0

[back to top]

Number of Participants With New Infections at the Pressure Ulcer Based on Clinical Signs and Symptoms Checklist (CCSC)

"Patients with at least 1 new infection after the foam dressing application at baseline until Visit 14 will be taken into account.~Infection is defined as presence of purulent exudates or 2 or more symptoms stated in the CCSC. For patients with existing infection at baseline, infection is defined as the development of an additional symptom or recurrence of the baseline symptom after it was completely healed." (NCT02863263)
Timeframe: 12 weeks

InterventionParticipants (Count of Participants)
Foam Dressing0
Foam Dressing With Povidone Iodine0

[back to top]

Number of Patients Achieving Early Study Completion Due to Complete Healing

Complete healing is defined as epithelial tissue covering 100% of the ulcer, with intact dermis and epidermis and without abrasion or ulceration. (NCT02863263)
Timeframe: 12 weeks

InterventionParticipants (Count of Participants)
Foam Dressing0
Foam Dressing With Povidone Iodine0

[back to top]

Pressure Ulcer Scale for Healing (PUSH) Score Measured Using PUSH Tool Version 3.0 At Week 12

"The PUSH score is measured at alternate visits (2-week intervals) starting from baseline and will be compared against baseline.~Minimum score= 0 Maximum score: 17 Higher score: worse outcome" (NCT02863263)
Timeframe: Week 12 (Or Last Observation Carried Forward)

Interventionscore on a scale (Median)
Foam Dressing8
Foam Dressing With Povidone Iodine7

[back to top]

Pressure Ulcer Size Measured Using A Ruler at Week 12

The ulcer area (for ulcers without re-epithelization) is measured at each visit after foam dressing application. A photograph of the ulcer is taken and a using a ruler (MediRuleⓇ) is used to measure its length and width to obtain the area in cm2. (NCT02863263)
Timeframe: Week 12 (Or Last Observation Carried Forward)

Interventioncm2 (Median)
Foam Dressing5.05
Foam Dressing With Povidone Iodine2.8

[back to top]

Microbial Levels

The CRT® Bacteria (Ivoclar Vivadent) saliva sample test is done on culture media that is specific for S. mutans and Lactobacillus. After incubation for 3 days the colonies are compared to photographic standards. (NCT03062605)
Timeframe: Baseline, 12 weeks

,
InterventionParticipants (Count of Participants)
Strep Mutans >10^5 at BaselineLactobacillus >10^5 at BaselineStrep Mutans >10^5 at 12 WeeksLactobacillus >10^5 at 12 Weeks
Control (CT)71554
Treatment(TX)111525

[back to top]

Number of Participants With Extended Hospital Stay Due to a Urinary Tract Infection (UTI)

Participants were monitored for up to 14 days. This is the number of participants who had a UTI in the hospital, extending their stay for more than seven days. (NCT03101371)
Timeframe: 14 days (+/- 2 days) from surgery

InterventionParticipants (Count of Participants)
Standard of Care Protocol Catheter Insertion0
Aseptic Protocol for Catheter Insertion1

[back to top]

Number of Participants With Closed Drainage System Disrupted During Placement of Catheter

Participants were monitored post surgery until time of discharge. This is the number of participants who had the closed drainage system disrupted during placement of catheter for back fill of the bladder during surgery. (NCT03101371)
Timeframe: Day 1 post op

InterventionParticipants (Count of Participants)
Standard of Care Protocol Catheter Insertion42
Aseptic Protocol for Catheter Insertion42

[back to top]

Number of Participants With a Catheter Associated Urinary Tract Infection (CAUTI)

Participants were monitored for up to 14 days. This was assessed with a rapid urine analysis (UA) test. A urinary tract infection was defined as >10^5 bacterial colony forming units per ML on urine culture regardless of symptoms. This is the number of participants who had at least one CAUTI during the time of observation. (NCT03101371)
Timeframe: Within 14 +/- 2 days post-surgery

InterventionParticipants (Count of Participants)
Standard of Care Protocol Catheter Insertion7
Aseptic Protocol for Catheter Insertion6

[back to top]

Number of Participants That Were Readmitted, Had Additional Clinic Visits or Went to the Emergency Department (ED) for Any Reason

Participants were monitored up to two weeks. This is the number of participants who had at least one readmission or emergency room visit during the time of observation. (NCT03101371)
Timeframe: Day 14 (+/- 2 days)

InterventionParticipants (Count of Participants)
Standard of Care Protocol Catheter Insertion0
Aseptic Protocol for Catheter Insertion1

[back to top]

Average Patient Satisfaction

Participants were monitored at 2 weeks. This was assessed using a Likert scale questionnaire (1 = not at all satisfied, 10 = extremely satisfied). Average patient satisfaction with the catheter was assessed. (NCT03101371)
Timeframe: Day14 (+/- 2 days)

Interventionscore on a scale (Mean)
Standard of Care Protocol Catheter Insertion8.17
Aseptic Protocol for Catheter Insertion8.6

[back to top]

Number of Patients That Used Antibiotics at the Time of Surgery and Post-surgery

Participants were monitored for up to 2 weeks. This is the number of participants that used any antibiotic during surgery and post-surgery. (NCT03101371)
Timeframe: Day 14 (+/- 2 days)

,
InterventionParticipants (Count of Participants)
Cefazolin (1st gen cephalosporin))Cefoxitin Cefuroxime / Cefotetan (2nd gen cephaloMetronidazoleClindamycinDoxycyclineGentamicin
Aseptic Protocol for Catheter Insertion39011606
Standard of Care Protocol Catheter Insertion36512503

[back to top]

Hospital Transfers Due to Infection

Probability that a transfer to a hospital is due to an infection (NCT03118232)
Timeframe: 18 months

InterventionTransfers (Number)
Decolonization1243
Routine Bathing1780

[back to top]

All Hospital Transfers

Probability that a discharge is to a hospital (NCT03118232)
Timeframe: 18 months

InterventionTransfers (Number)
Decolonization2388
Routine Bathing2857

[back to top]

Multidrug-resistant Organism (MDRO) Colonization (Secondary Manuscript)

Probability of colonization with any multidrug-resistant organism (MDRO): (MRSA, VRE, ESBL, CRE) (NCT03118232)
Timeframe: Once in baseline and once at end-intervention (month 15-18 of intervention period)

InterventionParticipants (Count of Participants)
Decolonization176
Routine Bathing307

[back to top]

Number of Participants With Vaginal or Urinary Symptoms After Surgery, Assessed by Validated Questionnaire (Modified PRO-CTCAE)

To determine and compare the number of participants with vaginal or urinary symptoms after treatment with chlorhexidine gluconate versus povidone iodine vaginal cleansing solutions. (NCT03305159)
Timeframe: Day of surgery to 24-48 hours after surgery

,
InterventionParticipants (Count of Participants)
Vaginal drynessVaginal burningUnusual vaginal dischargePain of burning with urinationVaginal itchiness
Control (Povidone Iodine)481097
Intervention (4% Chlorhexidine Gluconate)112514177

[back to top]

Number of Participants With a Deep Incisional or Organ/Space Infection

"Guided by CDC's National Healthcare Safety Network Surgical Site Infection reporting criteria (2017):~Deep Incisional Infection:~Occurs within 90 days post definitive fracture management; & involves fascial/muscle layers; & has at least one of the following:~deep incision purulent drainage~a deep incision that dehisces, or is opened by a surgeon, and organism is identified by microbiologic testing; or microbiologic testing is not performed & has at least one of the following: fever (> 38 °C); localized pain or tenderness~other evidence of deep incision infection on anatomical exam or imaging test~Organ/Space Infection:~Occurs within 90 days post definitive fracture management; & involves any part of the body deeper than the fascial/muscle layers; & has at least one of the following:~organ/space purulent drainage~organisms in organ/space identified by microbiologic testing~other evidence of organ/space infection on anatomical exam or imaging test" (NCT03385304)
Timeframe: Within 90 days of the patient's last planned fracture management surgery

InterventionParticipants (Count of Participants)
10% Povidone-iodine (1% Free Iodine) in Purified Water46
4% Chlorhexidine Gluconate (CHG) in Purified Water51

[back to top]

Number of Participants With a Superficial Incisional Surgical Site Infection (SSI)

"Guided by the Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network reporting criteria (2017):~Date of event for infection may occur from the date of fracture to 30 days after the definitive fracture management surgery; AND involves only skin and subcutaneous tissue of the incision; AND patient has at least one of the following:~purulent drainage from the superficial incision.~organisms identified from an aseptically obtained specimen from the superficial incision or subcutaneous tissue by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment~superficial incision that is deliberately opened by a surgeon, and culture or non-culture-based testing is not performed. AND patient has at least one of the following signs or symptoms: pain or tenderness; localized swelling; erythema; or heat.~diagnosis of a superficial incisional SSI by the surgeon." (NCT03385304)
Timeframe: Within 30 days of the patient's last planned fracture management surgery

InterventionParticipants (Count of Participants)
10% Povidone-iodine (1% Free Iodine) in Purified Water13
4% Chlorhexidine Gluconate (CHG) in Purified Water7

[back to top] [back to top]

Identify the Number of Preoperative Patients Positive for S. Aureus Using Collection Kits

To identify the number of patients in the preoperative setting who test positive for S. aureus. (NCT03638947)
Timeframe: Preoperative

Interventionnumber of participants (Number)
Standard of Care18
Swab Kit Plus Povidone-iodine Soap8

[back to top]

Quantitate the Reduction of S. Aureus Tranmission

Compare the number of S. aureus transmission events for patients who receive the standard presurgical preparation verses patients who receive decolonization interventions. (NCT03638947)
Timeframe: Up to 180 days following surgery

Interventionevents (Mean)
Standard of Care1.25
Swab Kit Plus Povidone-iodine Soap0.47

[back to top]

Number of Participants With Surgical Site Infection

Surgical site infection as defined by the Centers for Disease Control and Prevention National Healthcare Safety Network. (NCT04146116)
Timeframe: Within 30 days of surgery

InterventionParticipants (Count of Participants)
Nasal Povidone-iodine0

[back to top]

Number of Participants With Staphylococcus Aureus Nasal Colonization

A dry, sterile, rayon swab will be used to sample the anterior apex portion of the right and left nostril. This swab will be tested for S. aureus bacteria. This swab will be tested for S. aureus bacteria. If bacteria are found in either nostril, the participant is categorized as being colonized with S. aureus (e.g. carries the bacteria in their nose with no signs or symptoms of infection). (NCT04146116)
Timeframe: Within 24 hours after surgery

InterventionParticipants (Count of Participants)
Nasal Povidone-iodine2

[back to top]

Number of Participants With Staphylococcus Aureus Nasal Colonization

A dry, sterile, rayon swab will be used to sample the anterior apex portion of the right and left nostril. This swab will be tested for S. aureus bacteria. If bacteria are found in either nostril, the participant is categorized as being colonized with S. aureus (e.g. carries the bacteria in their nose with no signs or symptoms of infection). (NCT04146116)
Timeframe: Within 6 hours after first dose of povidone-iodine

InterventionParticipants (Count of Participants)
Nasal Povidone-iodine12

[back to top] [back to top] [back to top] [back to top]

Count of Participants Experiencing Adverse Events of Interest After Nasal Sprays

Participants were asked on day 3 whether they experienced the adverse event since baseline, then asked on day 5 whether they experienced the adverse event since day 3 (collected by questionnaire). Adverse events of interest include: Nasal burning/pain, headaches, ear pain, sneezing, and nose bleeds. (NCT04347954)
Timeframe: Assessed on days 3 and 5

,,
InterventionParticipants (Count of Participants)
Nasal burning or pain - Day 3Nasal burning or pain - Day 5Headaches - Day 3Headaches - Day 5Ear pain - Day 3Ear pain - Day 5Sneezing - Day 3Sneezing - Day 5Nose bleeds - Day 3Nose bleeds - Day 5
Isotonic Saline 0.9%4232114411
Povidone-Iodine 0.5%2232001100
Povidone-Iodine 2%131356229911

[back to top]

Mean Cycle Threshold (Ct) Values Through Day 3 as a Measure of Change in Viral Titers of SARS-CoV-2

"Nasopharyngeal swabs were obtained and quantitative reverse transcription-polymerase chain reaction (RT-PCR) testing was performed to determine the viral load in the nasopharynx.~Cycle threshold (Ct) denotes how many PCR cycles are required before the SARS-CoV-2 viral RNA reached a detectable level. Higher Ct values correspond to lower viral copy numbers. For reference, Ct values of 20 correspond to ~2.12 x 106 viral copies per milliliter, while a Ct value of 40 is undetectable and is considered the lower limit of detection of this RT-PCR test for SARS-CoV-2." (NCT04347954)
Timeframe: Day 1 (baseline), Day 1 (1 hour), Day 3

,,
Interventioncycles (Mean)
BaselineHour 1Day 3
Isotonic Saline 0.9%24.3625.7129.20
Povidone-Iodine 0.5%26.0326.4636.26
Povidone-Iodine 2%28.4227.4531.01

[back to top]

Count of Participants Normosmia, Microsmia, or Anosmia as a Measure of Change in the University of Pennsylvania Smell Identification Test (UPSIT)

Participants scratch test cards and attempt to identify the smell from a multiple choice set of options. Their scores are then computed and categorized as normosmia (normal), mild, moderate, or severe microsmia (loss of smell), or anosmia (total loss of smell). (NCT04347954)
Timeframe: Day 1 (baseline), Day 30

,,
InterventionParticipants (Count of Participants)
Anosmia - BaselineAnosmia - day 30Severe microsmia - baselineSevere microsmia - day 30Moderate microsmia - baselineModerate microsmia - day 30Mild microsmia - baselineMild microsmia - day 30Normosmia - baselineNormosmia - day 30
Isotonic Saline 0.9%2032202523
Povidone-Iodine 0.5%4011200238
Povidone-Iodine 2%5011213317

[back to top] [back to top] [back to top] [back to top] [back to top]

PVP-I Ease of Use

"Patients will rate the ease of use for PVP-I treatment on a scale from 1-5 after the initial use. Lower scores indicate increased ease of use (1=easy) while higher scores indicate increased difficulty (5=impossible)." (NCT04364802)
Timeframe: 3 weeks

Interventionunits on a scale (Mean)
Healthcare Workers - PVP-I4.48
Inpatients - PVP-I4.43
Community - PVP-I4.77

[back to top]

PVP-I Comfort

"Patients will rate the comfort of PVP-I treatment on a scale from 1-5 after the initial use. Lower scores indicate increased comfort (1=not so bad) while higher scores indicate discomfort (5=worst pain of my life)." (NCT04364802)
Timeframe: 3 weeks

Interventionunits on a scale (Mean)
Healthcare Workers - PVP-I3.25
Inpatients - PVP-I4.00
Community - PVP-I3.00

[back to top]

Percent of Patients Testing Positive for COVID-9.

Percent of patients that become positive for COVID-19 during the study. (NCT04364802)
Timeframe: 2 weeks

Interventionpercentage of patients (Number)
Inpatients - Control0
Inpatients - PVP-I0

[back to top]

Percent of Healthcare Workers Testing Positive for COVID-19.

Percent of healthcare workers that become positive for COVID-19 during the study. (NCT04364802)
Timeframe: 3 weeks

Interventionpercentage of healthcare workers (Number)
Healthcare Workers - Control0
Healthcare Workers - PVP-I0

[back to top]

Percent of Community Participants Testing Positive for COVID-9.

Percent of community participants that become positive for COVID-19 during the study. (NCT04364802)
Timeframe: 3 weeks

Interventionpercentage of community participants (Number)
Community - Control0
Community - PVP-I0

[back to top]

Number of Participants With Early Viral Clearance

Viral clearance is defined as two negative RT-PCR (of swabs from oropharynx and nasopharynx) results at least 24 hours apart (NCT04410159)
Timeframe: Day 6

InterventionParticipants (Count of Participants)
Povidone-iodine5
Essential Oils4
Tap Water1
Control0

[back to top]

Number of Participants With Negative RT-PCR Results

RT-PCR (swabs from oropharynx and nasopharynx) taken at day 12 (NCT04410159)
Timeframe: Day 12

InterventionParticipants (Count of Participants)
Povidone-iodine5
Essential Oils4
Tap Water2
Control1

[back to top]

Number of Patients That Progress to More Severe Disease

Presence of signs and symptoms of more severe COVID19 Based symptoms diary and clinical evaluation (NCT04410159)
Timeframe: Day 12

InterventionParticipants (Count of Participants)
Povidone-iodine0
Essential Oils0
Tap Water0
Control0

[back to top]

Number of Patients With Abnormal Laboratory Findings

Abnormal absolute lymphocytic count Abnormal C-reactive protein (NCT04410159)
Timeframe: Day 0-14

InterventionParticipants (Count of Participants)
Povidone-iodine0
Essential Oils0
Tap Water0
Control0

[back to top]

Number of Patients With Abnormal Radiological Findings

abnormal chest x-ray or CT scan (NCT04410159)
Timeframe: Day 0-14

InterventionParticipants (Count of Participants)
Povidone-iodine0
Essential Oils0
Tap Water0
Control0

[back to top]